{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.24759"}, {"@name": "filename", "#text": "9235_miola_ac_me_bot.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE ESTADUAL PAULISTA \n\n\u201cJ\u00daLIO DE MESQUITA FILHO\u201d \n\nFACULDADE DE MEDICINA \n\n \n\n \n\nAnna Carolina Miola \n\n \n\n \n\nEFIC\u00c1CIA E SEGURAN\u00c7A DO CREME DE COLCHICINA 0,5% \n\nVERSUS TERAPIA FOTODIN\u00c2MICA COM AMINOLEVULINATO DE \n\nMETILA NO TRATAMENTO DO CAMPO DE CANCERIZA\u00c7\u00c3O \n\nCUT\u00c2NEO: UM ENSAIO CL\u00cdNICO RANDOMIZADO \n\n \n\nDisserta\u00e7\u00e3o apresentada \u00e0 Faculdade de \nMedicina de Botucatu, Universidade Estadual \n\nPaulista \u201cJ\u00falio de Mesquita Filho\u201d, Campus de \nBotucatu, para obten\u00e7\u00e3o do t\u00edtulo de Mestre em \nPatologia. \n\n \n\n \n\n Orientador: Prof.  Dr. H\u00e9lio Amante Miot \n\n  \n\n \n\n \n\n \n\nBotucatu \n\n2017  \n\n\n\n \n \n\nUNIVERSIDADE ESTADUAL PAULISTA \u201cJ\u00daLIO DE MESQUITA FILHO\u201d  \n\nFACULDADE DE MEDICINA - CAMPUS DE BOTUCATU \n\n \n\n \n\n \n\n \n\nEFIC\u00c1CIA E SEGURAN\u00c7A DO CREME DE COLCHICINA 0,5% VERSUS TERAPIA \n\nFOTODIN\u00c2MICA COM AMINOLEVULINATO DE METILA NO TRATAMENTO DO CAMPO DE \n\nCANCERIZA\u00c7\u00c3O CUT\u00c2NEO: UM ENSAIO CL\u00cdNICO RANDOMIZADO \n\n \n\n \n\n \n\n \n\nMestrando: Anna Carolina Miola \n\nOrientador: Prof. Dr. H\u00e9lio Amante Miot \n\n \n\n \n\n \n\n \n\n \nDisserta\u00e7\u00e3o apresentada \u00e0 Faculdade de \n\nMedicina de Botucatu, Universidade \nEstadual Paulista \u201cJ\u00falio de Mesquita Filho\u201d, \nCampus de Botucatu, para obten\u00e7\u00e3o do t\u00edtulo  \n\nde Mestre em Patologia \n \n\n \n\nBotucatu \n\n2017 \n\n\n\n \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n  \n\n\n\n3 \n \n\n \n\nSUM\u00c1RIO \n\n \n\nDEDICAT\u00d3RIA ................................................................................................................................ 4 \n\nAGRADECIMENTOS ESPECIAIS  ....................................................................................................... 5 \n\nAGRADECIMENTOS ........................................................................................................................ 6 \n\nLIST A DE ABREVIAT URAS / SIGLAS .................................................................................................. 8 \n\nLIST A DE S\u00cdMBOLOS ...................................................................................................................... 9 \n\nRESUMO ..................................................................................................................................... 10 \n\nABST RACT .................................................................................................................................. 11 \n\n1.REVIS\u00c3O DE LIT ERAT URA .......................................................................................................... 12 \n\n1.1 Queratoses act\u00ednicas e campo de canceriza\u00e7\u00e3o cut\u00e2neo............................................................... 12 \n\n1.2 T ratamentos dispon\u00edveis ......................................................................................................... 14 \n\n1.3 Colchicina............................................................................................................................ 17 \n\n1.4 T erapia Fotodin\u00e2mica............................................................................................................. 19 \n\n1.5 Refer\u00eancias.......................................................................................................................... 21 \n\n2. OBJET IVOS .......................................................................................................................... 24 \n\n3. MANUSCRITO ....................................................................................................................... 25 \n\n4. CONCLUS\u00d5ES ...................................................................................................................... 41 \n\n5. PERSPECT IVAS .................................................................................................................... 42 \n\nANEXO 1: T ermo de Consentimento Livre e Esclarecido ....................................................................... 43 \n\nANEXO 2: Randomiza\u00e7\u00e3o dos antebra\u00e7os dos pacientes ....................................................................... 44 \n\nANEXO 3: Escala de fotoenvelhecimento dos antebra\u00e7os ...................................................................... 45 \n\nANEXO 4: Escala de Gravidade de Queratoses Act\u00ednicas ...................................................................... 46 \n\nANEXO 5: Parecer do Comit\u00ea de \u00c9tica em Pesquisa............................................................................. 47 \n\n \n\n\n\n4 \n \n\n \n\nDEDICAT\u00d3RIA \n\n \n\n \n\nA Deus, por guiar meu caminho sempre. Por me iluminar e me manter em p\u00e9 mesmo nas \n\nhoras mais dif\u00edceis. \n\n \n\nAos meus pais, Claudio e Sueli, por todo o esfor\u00e7o e dedica\u00e7\u00e3o na minha forma\u00e7\u00e3o. Nada \n\nseria poss\u00edvel sem seu apoio, sempre incondicional.  \n\n \n\nAo meu irm\u00e3o, Daniel, pelo apoio \u00e0 dist\u00e2ncia e por toda a ajuda imprescind\u00edvel com a \n\ninform\u00e1tica para o meu trabalho. \n\n \n\nAo meu noivo, Arley, pelo apoio, compreens\u00e3o e aux\u00edlio de in\u00fameros modos, \n\nindispens\u00e1veis durante todo o per\u00edodo, da coleta ao desenvolvim ento da tese. \n\n \n\nA todos familiares e amigos que sempre me incentivaram durante todo o per\u00edodo , \n\nespecialmente meus tios Jos\u00e9 e Denise, que sempre me apoiaram, desde a adolesc\u00eancia, a continuar \n\nestudando e n\u00e3o desistir dos meus sonhos. \n\n \n\nAos meus c\u00e3es Pitty (in memoriam ), Marley e \u00darsula, por todas as alegrias que me \n\nproporcionaram e carinho dispensados a mim do modo que lhes \u00e9 poss\u00edvel.  \n\n \n\n\n\n5 \n \n\n \n\nAGRADECIMENTOS ESPECIAIS \n\n \n\n \n\nAo meu orientador, Prof. H\u00e9lio Amante Miot,  \n\nPor toda dedica\u00e7\u00e3o e incentivo \u00e0 ci\u00eancia, desde as primeiras reuni\u00f5es at\u00e9 as fases finais \n\nde reda\u00e7\u00e3o. Pela paci\u00eancia e cuidado com nosso projeto. Por sempre me estimular a fazer o meu \n\nmelhor. Exemplo de m\u00e9dico, dermatologista e pesquisador.  Amigo que essa \u00f3tima experi\u00eancia me \n\nproporcionou. \n\n \n\n\u00c0 Prof.\u00aa Luciana Patr\u00edcia Fernandes Abbade,  \n\nPor estar sempre presente, mesmo com a dist\u00e2ncia f\u00edsica, empenhada em sempre buscar \n\no melhor para esse projeto. \n\n \n\nAo Prof. Juliano Vilaverde Schmitt, \n\nPor todo apoio e dedica\u00e7\u00e3o desde o in\u00edcio da orienta\u00e7\u00e3o.  \n\n \n\nA minha amiga Eliane Roio, pela amizade, apoio e cuidado com o nosso projeto  durante \n\ntodo o per\u00edodo de execu\u00e7\u00e3o .  \n\n \n\n\n\n6 \n \n\n \n\nAGRADECIMENTOS \n\n \n\n \n\n \n\nAos volunt\u00e1rios que participaram do estudo,  \n\nPela confian\u00e7a que depositaram em mim.  \n\n \n\nAos residentes, contratados e docentes do Departamento de Dermatologia da Faculdade \n\nde Medicina de Botucatu, \n\nPelo apoio e aprendizado que recebi durante todo o projeto.  \n\n \n\n\u00c0 divis\u00e3o de Dermatologia, seus contratados e docentes e  \u00e0 Faculdade de Medicina de \n\nRibeir\u00e3o Preto da USP,  \n\nPelo conhecimento e forma\u00e7\u00e3o concedidos a mim. Anos vividos que jamais esquecerei.  \n\n \n\nAo Departamento de Dermatologia e \u00e0 Faculdade de Medicina de Botucatu, \n\nPelo acolhimento e pelas oportunidades \u00fanicas de crescimento profissional que t\u00eam me \n\nproporcionado. \n\n \n\n  \n\n\n\n7 \n \n\n \n\nTrabalho desenvolvido no ambulat\u00f3rio de Dermatologia \n\nHC-UNESP \n\n \n\n \n\n\n\n8 \n \n\n \n\nLISTA DE ABREVIATURAS / SIGLAS \n \n\n \n\n5-FU \u2013 5-fluorouracil \n\nAK \u2013 do ingl\u00eas Actinic Keratosis: queratose act\u00ednica \nALA \u2013 \u00e1cido 5-delta aminolevul\u00ednico \n\nATA \u2013 \u00e1cido tricloroac\u00e9tico \nBeta HCG \u2013 gonadotrofina cori\u00f4nica humana tipo beta \nCEC \u2013 carcinoma espinocelular \n\nCEP \u2013 Comit\u00ea de \u00c9tica em Pesquisa \ndp \u2013 desvio-padr\u00e3o \nFMB-Unesp \u2013 Faculdade de Medicina de Botucatu - Universidade Estadual Paulista \u201cJ\u00falio de Mesquita \n\nFilho\u201d \nHSCORE \u2013 escore histol\u00f3gico \nITT \u2013 do ingl\u00eas Intention To Treat: an\u00e1lise tipo inten\u00e7\u00e3o de tratamento  \n\nKi67 \u2013 prote\u00edna Ki67 \nKIN \u2013 do ingl\u00eas Keratinocyte Intraepithelial neoplasia: neoplasia intraepitelial queratinoc\u00edtica \n\nLED \u2013 do ingl\u00eas Light Emitting Diode: diodo emissor de luz \nLOCF \u2013 do ingl\u00eas Last Observation Carried Forward \nMAL \u2013 do ingl\u00eas methyl aminolevulinate: aminolevulinato de metila \n\np53 \u2013 prote\u00edna p53  \np.ex. \u2013 por exemplo \nPDT-MAL \u2013 do ingl\u00eas Photodynamic Therapy with Methyl Aminolevulinate \n\nPVC \u2013 do ingl\u00eas Polyvinyl Chloride: policloreto de vinila \nQA \u2013 queratose act\u00ednica \nRUV \u2013 radia\u00e7\u00e3o ultravioleta \n\nSCC \u2013 do ingl\u00eas Squamous Cell Carcinoma: carcinoma espinocelular \nsd \u2013 do ingl\u00eas standard deviation: desvio padr\u00e3o \nSFC \u2013 do ingl\u00eas Skin Field Cancerization: campo de canceriza\u00e7\u00e3o cut\u00e2neo \n\nTFD \u2013 terapia fotodin\u00e2mica \nUNESP \u2013 Universidade Estadual Paulista \u201cJ\u00falio de Mesquita Filho\u201d \n\nUVA \u2013 radia\u00e7\u00e3o ultravioleta tipo A \nUVB \u2013 radia\u00e7\u00e3o ultravioleta tipo B \n \n\n \n  \n\n\n\n9 \n \n\n \n\nLISTA DE S\u00cdMBOLOS \n\n \n\u00ae - Marca Registrada \n \n\n\n\n10 \n \n\n \n\nRESUMO \n \n\n \n\nFundamentos: Campo de canceriza\u00e7\u00e3o cut\u00e2neo representa uma \u00e1rea com altera\u00e7\u00f5es gen\u00f4micas induzidas pela \n\nradia\u00e7\u00e3o ultravioleta, cujo sinal de atividade s\u00e3o as queratoses act\u00ednicas (QA). T ratamentos que visem sua \n\nestabiliza\u00e7\u00e3o podem reduzir a incid\u00eancia de QA e de tumores cut\u00e2neos n\u00e3o melanoma.  Estudos em terapia \n\nfotodin\u00e2mica com metil aminolevulinato (TFD-MAL) no tratamento do campo de canceriza\u00e7\u00e3o cut\u00e2neo mostram \n\nredu\u00e7\u00e3o de at\u00e9 89% na contagem de QA, j\u00e1 com colchicina t\u00f3pica, h\u00e1 redu\u00e7\u00e3o de at\u00e9 78%. At\u00e9 o  momento, n\u00e3o \n\nh\u00e1 estudos comparando colchicina com TFD-MAL. Esse trabalho objetiva avaliar efic\u00e1cia e seguran\u00e7a de \n\ncolchicina 0,5% creme versus T FD-MAL no tratamento do campo de canceriza\u00e7\u00e3o dos antebra\u00e7os. \n\nCasu\u00edstica e m \u00e9todos: Ensaio cl\u00ednico aberto, controlado, randomizado, envolvendo 36 pacientes do ambulat\u00f3rio \n\nde Dermatologia da UNESP-Botucatu, com 3-10 QAs em cada antebra\u00e7o, tratados (cada antebra\u00e7o) com creme \n\nde colchicina 0,5% (2x/dia por 10 dias) ou uma sess\u00e3o de TFD-MAL; reavaliados ap\u00f3s 60 dias. A a valia\u00e7\u00e3o \n\ncl\u00ednica foi realizada pela contagem de QAs, seus subtipos cl\u00ednicos, sua escala de gravidade e escala de \n\nfotoenvelhecimento dos antebra\u00e7os. Avalia\u00e7\u00e3o histopatol\u00f3gica foi realizada pelo escore KIN (Keratinocyte \n\nIntraepithelial Neoplasia), atrofia epitelial e imunohistoqu\u00edmica de p53 e Ki67. T odos os pacientes inclu\u00eddos no \n\nestudo e randomizados fizeram parte da popula\u00e7\u00e3o ITT (intention to treat). Os dados do \u00fanico dropout foram \n\nimputados como LOCF (last observed carried forward). \n\nResultados: Foram inclu\u00eddos 36 participantes: 50% eram do sexo masculino, com idade m\u00e9dia (dp) de 70,9 \n\n(8,6) anos e predomin\u00e2ncia de pacientes fototipos I e  II (89%). O  clearance total de QAs ocorreu em 6 (17%) de \n\nCOL e 7 (19%) de MAL-PDT  (p=0,76), e clearance parcial (> 50%) foi alcan\u00e7ado em 16 (44%) dos antebra\u00e7os \n\nCOL e 24 (67%) MAL-PDT  (p=0,07). Houve redu\u00e7\u00e3o significativa no escore da escala de fotoenvelhecimento \n\npara COL e TFD-MAL (-6% vs -6%), escore de gravidade de QA (-65% vs -73%), subtipos cl\u00ednicos das QAs \n\npresentes e contagem de QA (-45% vs -40%), ap\u00f3s as interven\u00e7\u00f5es (p<0,01), sem diferen\u00e7as significativas entre \n\nos grupos. Houve redu\u00e7\u00e3o no escore KIN em ambos os grupos (p<0,01), normalizado em 28% dos pacientes \n\nMAL-PDT  e 20% em COL. Houve redu\u00e7 \u00e3o da atrofia epitelial ap\u00f3s 60 dias (p<0,01), sem diferen\u00e7as entre os \n\ntratamentos (p=0,58). Houve redu\u00e7\u00e3o significativa do escore Ki67 em ambos os tratamentos: 15% em COL e 9% \n\nem MAL-PDT , sem diferen\u00e7a entre os grupos (p=0,32). Houve redu\u00e7\u00e3o do escore de p53 em 27% no grupo \n\nCOL, por\u00e9m, um aumento de 4% na MAL-PDT  (p<0,05). Efeitos adversos foram relatados em ambos os grupos: \n\n69% em COL e 67% em T FD-MAL. N\u00e3o houve evento adverso grave. \n\nConclus\u00e3o: Colchicina 0,5% creme e T FD-MAL s\u00e3o eficazes e seguros no tratamento do campo de \n\ncanceriza\u00e7\u00e3o cut\u00e2neo. \n\n \n\nPalavras-chave: Campo de canceriza\u00e7\u00e3o, Carcinoma espinocelular, Ceratose act\u00ednica, Colchicina, \n\nDermatologia, Fotoquimioterapia, Oncologia, Quimiopreven\u00e7\u00e3o, T erapia fotodin\u00e2mica. \n\n\n\n11 \n \n\n \n\nABSTRACT \n \n\n \n\nBackground: Skin field cancerization is an area with genomic alterations induced by ultraviolet radiation, and \n\nactinic keratosis (AK) is a sign of its activity. Treatments to stabilize it may reduce the incidence of non -melanoma \n\nskin cancers and AK. Photodynamic therapy with methyl aminolevulinate (TFD-MAL) in the treatment of skin field \n\ncancerization shows a reduction of up to 89% in the AK count, and topical colchicine, up to  78% of reduction. To  \n\ndate, there are no studies comparing colchicine with PDT-MAL. The aim of this study was to evaluate the efficacy \n\nand safety of colchicine 0.5% cream versus PDT-MAL in skin field cancerization treatment of the forearms. \n\nPatients and methods: A randomized, controlled clinical trial involving 36 patients from the UNESP-Botucatu \n\nDermatology outpatient clinic, with three to 10 AKs in each forearm, treated (each forearm) with colchicine cream \n\n(2x / day for 10 days) and one session of PDT-MAL. Reassessed after 60 days. Clinical evaluation was \n\nperformed by AK count, its clinical subtypes, severity scale and forearm photoaging scale. Histopathological \n\nevaluation performed by KIN (Keratinocyte Intraepithelial Neoplasia), epithelial atrophy and \n\nimmunohistochemistry of p53 and Ki67. All patients included in the study and randomized were p art of the ITT \n\npopulation (intention to treat). The only dropout was analyzed through LOCF (last observation carried forward). \n\nResults: Thirty-six participants were included: 50% were males, mean age (SD) of 70.9 (8.6) years and \n\npredominance of phototype I and II patients (89%). Total clearance of AK occurred in 6 (17%) of COL and 7 \n\n(19%) of MAL-PDT (p = 0.76), and partial clearance (> 50%) was achieved in 16 (44%) of COL and 24 (67%) of \n\nMAL-PDT (p = 0.07). There was a significant reduction in the photodamage scale for COL and PDT-MAL (-6% vs \n\n-6%), AK severity score (-65% vs -73%), clinical subtypes of the present AK and AK (-45% vs -40%) after \n\ninterventions (p&lt;0.01), with no significant differences between the groups (p> 0.24). There was a reduction in \n\nKIN score in both groups (p&lt;0.01), normalized in 28% of MAL-PDT patients and 20% in COL. There was \n\nreduction of epithelial atrophy after 60 days (p&lt;0.01), with no differences between treatments (p = 0.58). There \n\nwas a significant reduction of the Ki67 score in both treatments: 15% in COL and 9% in MAL-PDT, with no \n\ndifference between groups (p = 0.32). There was a  reduction of the p53 score in 27% in the COL group, but a 4% \n\nincrease in MAL-PDT (p&lt;0.05). Adverse effects were reported in both groups: 69% in COL and 67% in PDT-\n\nMAL. There was no serious adverse event. \n\nConclusion: Colchicine 0.5% cream and TFD-MAL are effective and safe in skin field cancerization treatment. \n\n \n\nKeywords: Actinic keratosis, Chemoprevention, Colchicin, Dermatology, Field cancerization, Oncology, \n\nPhotochemoterapy, Photodynamic therapy, Squamous cell carcinoma. \n\n\n\n12 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\n1.REVIS\u00c3O DE LITERATURA \n\n \n\n1.1 Queratoses act\u00ednicas e campo de canceriza\u00e7\u00e3o cut\u00e2neo \n\n \n\nQueratoses act\u00ednicas (QA), ceratoses act\u00ednicas ou queratoses solares, s\u00e3o neoplasias \n\ncut\u00e2neas pr\u00e9-malignas, resultantes, principalmente, da fotoexposi\u00e7\u00e3o cr\u00f4nica. Acometem \n\nespecialmente sujeitos de pele clara, adultos e idosos, nas \u00e1reas fotoexpostas 1. \n\nS\u00e3o formadas por prolifera\u00e7\u00f5es at\u00edpicas de queratin\u00f3citos intraepiteliais e, com o tempo, \n\napresentam risco de evoluir para carcinoma espinocelular (CEC) de 0,025 a 20% por ano 2. \n\nPacientes de fototipos I e II de Fitzpatrick, imunocomprometidos, idosos e com \n\nantecedente de fotoexposi\u00e7\u00e3o cr\u00f4nica sem fotoprote\u00e7\u00e3o, constituem o grupo de maior risco para \n\ndesenvolvimento de QAs2. Isso decorre da maior a\u00e7\u00e3o da radia\u00e7\u00e3o ultravioleta (RUV) na pele \n\nmenos melanizada, al\u00e9m da redu\u00e7\u00e3o do reparo ao dano gen\u00f4mico induzido pela RUV no seu \n\nepit\u00e9lio. \n\nAs QAs desenvolvem-se, clinicamente, como les\u00f5es maculares, papulosas ou m\u00e1culo -\n\npapulosas, confluentes ou n\u00e3o, cobertas por escamas aderentes e hiperquerat\u00f3sicas, com cerca \n\nde 0,5 a 1 cm (Figura 1). Apresentam crescimento lento, e ocorrem principalmente nas \u00e1reas \n\nmais expostas \u00e0 luz solar, como colo, face, couro cabeludo, antebra\u00e7os e dorso das m\u00e3os. QAs \n\npodem evoluir com infiltra\u00e7\u00e3o, crescimento r\u00e1pido, sangramento e ulcera\u00e7\u00e3o, sinais que indicam \n\nposs\u00edvel progress\u00e3o para CEC1,3. \n\n A apresenta\u00e7\u00e3o cl\u00ednica das les\u00f5es foi dividida por Olsen em tr\u00eas graus: Grau I (vis\u00edvel e \n\nlevemente palp\u00e1vel), Grau II (vis\u00edvel e palp\u00e1vel), Grau III (francamente vis\u00edvel e \n\nhiperquerat\u00f3tica)4, por\u00e9m, essa classifica\u00e7\u00e3o ainda n\u00e3o se baseia em crit\u00e9rios histol\u00f3gicos ou da \n\nbiologia das les\u00f5es (p.ex. atividade de prolifera\u00e7\u00e3o e apoptose). A maior parte dos estudos ainda \n\nemprega a contagem de QAs por \u00e1rea como sinal de atividade do campo de canceri za\u00e7\u00e3o \n\ncut\u00e2neo1,5. \n\nGeralmente, pacientes com diagn\u00f3stico de QA possuem mais de uma les\u00e3o em uma \n\nmesma \u00e1rea.  M\u00faltiplas QAs incidentes em uma mesma regi\u00e3o caracterizam \u2013 clinicamente \u2013 um \n\ncampo de canceriza\u00e7\u00e3o cut\u00e2neo em atividade6. \n\n \n\n\n\n13 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\n \n\n \nFigura 1. Queratoses act\u00ednicas: les\u00f5es eritematosas, hiperquerat\u00f3sicas e infiltradas em \u00e1rea de pele \n\ndanificada pela exposi\u00e7\u00e3o solar cr\u00f4nica (Fonte: Departamento de Dermatologia -FMB-Unesp). \n\n \n\nDescrito pela primeira vez em 1953 por Slaughter em pacientes com CEC oral, o campo \n\nde canceriza\u00e7\u00e3o compreende uma \u00e1rea de tegumento aparentemente normal, por\u00e9m, com \n\naltera\u00e7\u00f5es subcl\u00ednicas e multifocais, composta por c\u00e9lulas gene ticamente alteradas, teoria que \n\njustificaria a recorr\u00eancia de tumores considerados completamente excisados \u00e0 histopatologia ou \n\nsurgimento de novas neoplasias em \u00e1reas adjacentes7. \n\nO conceito de campo de canceriza\u00e7\u00e3o  cut\u00e2neo sugere que a pele aparentemente normal \n\nque circunda as QAs seja a base da expans\u00e3o clonal de c\u00e9lulas geneticamente alteradas, o que \n\nexplicaria a ocorr\u00eancia de novas QAs ou outras neoplasias cut\u00e2neas em uma mesma \u00e1rea \n\ntegumentar, al\u00e9m da recorr\u00eancia local de tumores considerados completamente excisados pela \n\nan\u00e1lise histopatol\u00f3gica8. \n\nRecentemente, o campo de canceriza\u00e7\u00e3o cut\u00e2neo vem sendo intensamente estudado \n\ndevido a sua import\u00e2ncia cl\u00ednica, pois sua estabiliza\u00e7\u00e3o pode prevenir o surgimento de \n\nneoplasias, sua recorr\u00eancia ou a evolu\u00e7\u00e3o das les\u00f5es j\u00e1 existentes (Figura 2)9. Esses estudos \n\nt\u00eam utilizado a contagem de QAs, seu di\u00e2metro e a erup\u00e7\u00e3o de novos tumores como medidas \n\ncl\u00ednicas indiretas de atividade do campo de canceriza\u00e7\u00e3o cut\u00e2neo, bem como an\u00e1lise de d\u00edm eros \n\nde ciclobutano pirimidina, express\u00e3o imunohistoqu\u00edmica de p53, Ki67, survivina, tenascina-C, \n\nentre outros. Entretanto, ainda n\u00e3o h\u00e1 consenso na literatura quanto a par\u00e2metros cl\u00ednicos ou \n\nhistol\u00f3gicos que possam medir sua atividade 6. \n\nTendo em vista o envelhecimento da popula\u00e7\u00e3o, a maior exposi\u00e7\u00e3o \u00e0 RUV e o aumento \n\nda incid\u00eancia de neoplasias cut\u00e2neas, terap\u00eauticas que visem \u00e0 estabiliza\u00e7\u00e3o da atividade do \n\n\n\n14 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\ncampo de canceriza\u00e7\u00e3o podem contribuir para a redu\u00e7\u00e3o da incid\u00eancia de QA e outras \n\nneoplasias malignas da pele, especialmente, em popula\u00e7\u00f5es suscept\u00edveis 1. \n\n \n\n \n\nFigura 2. Campo de canceriza\u00e7\u00e3o cut\u00e2neo: m\u00faltiplas queratoses act\u00ednicas (identificadas) em antebra\u00e7o \nde idoso exposto cronicamente ao sol (Fonte: Departamento de Dermatologia -FMB-Unesp). \n\n \n\n1.2 Tratamentos dispon\u00edveis \n\n \n\nO objetivo do tratamento das QAs e do campo de canceriza\u00e7\u00e3o cut\u00e2neo \u00e9 evitar o risco \n\nde progress\u00e3o para les\u00f5es malignas e diminuir o n\u00famero de les\u00f5es pr\u00e9 -malignas na \u00e1rea \n\nafetada. Atualmente, h\u00e1 v\u00e1rias modalidades terap\u00eauticas, que devem ser escolhidas de acordo \n\ncom a regi\u00e3o a ser tratada: o n\u00famero de les\u00f5es, a presen\u00e7a ou n\u00e3o de imunossupress\u00e3o ou \n\noutras comorbidades, al\u00e9m do custo e tolerabilidade do tratamento, que consequentemente \n\ninfluenciar\u00e3o na ader\u00eancia do paciente 6. \n\nA crioterapia com nitrog\u00eanio l\u00edquido \u00e9 o tratamento mais utilizado para QAs 10. \n\nGeralmente bem tolerada, de f\u00e1cil acesso e com bons resultados cl\u00ednicos e histopatol\u00f3gicos: \n\nresposta cl\u00ednica de 83% com um tempo de congela\u00e7\u00e3o superior a 20 segundos. Podem ocorrer \n\ndesconforto na aplica\u00e7\u00e3o e hipocromia persistente p\u00f3s-procedimento. A crioterapia, entretanto, \n\ntrata apenas as les\u00f5es vis\u00edveis de QAs, sem efeito no epit\u00e9lio genomicamente inst\u00e1vel do campo \n\nde canceriza\u00e7\u00e3o 11. \n\nA curetagem associada \u00e0 eletrocirurgia \u00e9 uma modalidade altamente eficaz para o \n\ntratamento de QAs. \u00c9 utilizada especialmente para les\u00f5es hiperquerat\u00f3ticas e infiltradas, por\u00e9m \n\n\n\n15 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\ntamb\u00e9m fica restrita ao tratamento de um n\u00famero limitado de QAs e n\u00e3o trata o campo de \n\ncanceriza\u00e7\u00e3o cut\u00e2neo como um todo 12. \n\nO laser de CO2 pode ser utilizado no tratamento de QAs. Com uma \u00fanica sess\u00e3o, ap\u00f3s \n\n90 dias, obteve-se taxa de resposta completa de 64%; entretanto, h\u00e1 recidiva da les\u00e3o de 71% 13. \n\nAl\u00e9m disso, o laser de CO2, assim como a crioterapia, trata somente as QAs vis\u00edveis.  \n\nO 5-fluorouracil (5FU) \u00e9 droga quimioter\u00e1pica t\u00f3pica, antimetab\u00f3lica, inibidora da s\u00edntese \n\ndo DNA.  Utilizada em concentra\u00e7\u00f5es que variam de 0,5 a 5%, pode ser utilizado na forma de \n\ncreme ou em peelings semanais.  Apresenta boa resposta terap\u00eautica, com redu\u00e7\u00e3o de at\u00e9 80% \n\nna contagem de QAs14, e a\u00e7\u00e3o concomitante no fotodano, estabilizando, consequentemente, o \n\ncampo de canceriza\u00e7\u00e3o.  Entretanto, seus efeitos colaterais podem levar \u00e0 interrup\u00e7\u00e3o do \n\ntratamento: eritema, dor, edema e ulcera\u00e7\u00e3o nos casos mais graves 14-16. \n\nO imiquimode \u00e9 um imunomodulador t\u00f3pico, agonista dos receptores toll-like tipo 7. Age \n\nestimulando a imunidade celular local e, consequentemente, leva \u00e0 destrui\u00e7\u00e3o da les\u00e3o por \n\napoptose. Apresenta taxa de clearance completo de QAs de 57,1% e parcial de 72,1%, versus \n\nplacebo, com 2,2% e 4,3%, respectivamente 9. \u00c9 dispon\u00edvel nas formula\u00e7\u00f5es de 3,75% e 5%, \n\npode causar eritema, edema e desconforto local vari\u00e1vel, assim como o 5-FU10-17. \n\nO mebutato de ingenol \u00e9 um novo agente  ativo extra\u00eddo da planta Euphorbia peplus \n\n(Figura 3), com mecanismo de a\u00e7\u00e3o pouco conhecido, por\u00e9m com evidente efeito citot\u00f3xico \n\ndireto e a\u00e7\u00e3o na resposta imune celular mediada por neutr\u00f3filos.  Apresenta clareamento parcial \n\nde 75% e total de 42% das QAs, com a vantagem do tempo curto de tratamento (2 a 3  dias).  \n\nSeus efeitos colaterais s\u00e3o leves a moderados e representados por irrita\u00e7\u00e3o, eritema (em dois \n\nter\u00e7os dos casos), dor, ves\u00edculas, p\u00fastulas e crostas, entretanto, com per\u00edodo r\u00e1pido de \n\nrecupera\u00e7\u00e3o18. \n\n \n\n  \n\n\n\n16 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\nFigura 3. Planta Euphorbia peplus, fonte de extra\u00e7\u00e3o do mebutato de ingenol, e sua estrutura qu\u00edmica. \n\n(Fonte: https://projects.ncsu.edu/cals/plantbiology/ncsc/deployed/sliks/Euphorbia_peplus.htm). \n\n \n\nA tretino\u00edna, ou \u00e1cido retinoico, tamb\u00e9m pode ser utilizada na estabiliza\u00e7\u00e3o do campo de \n\ncanceriza\u00e7\u00e3o cut\u00e2neo, pois promove a redu\u00e7\u00e3o  de atipias nos queratin\u00f3citos, aumenta o n\u00famero \n\nde c\u00e9lulas de Langerhans na \u00e1rea de aplica\u00e7\u00e3o , a espessura epitelial e reduz p53 e BAX. Houve \n\nredu\u00e7\u00e3o de 45% do n\u00famero de QAs em estudo feito com tretino\u00edna 0,05%, versus redu\u00e7\u00e3o de \n\n23% no grupo placebo, com filtro solar19,20. \n\nA fotoprote\u00e7\u00e3o efetiva reduz a contagem de QAs. Em estudo controlado, usu\u00e1rios de \n\nfiltro solar reduziram em at\u00e9 40% a incid\u00eancia de novas QAs 21 no per\u00edodo de seis meses. \n\nO fotoprotetor associado \u00e0 enzima fotoliase pode ser usado como adjuvante no \n\ntratamento do campo de canceriza\u00e7\u00e3o. A fotoliase \u00e9 enzima reparadora do DNA, ativada por luz \n\nvis\u00edvel, que mostrou benef\u00edcio no tratamento do campo de canceriza\u00e7\u00e3o, pois leva \u00e0 melhora dos \n\npar\u00e2metros cl\u00ednicos e histopatol\u00f3gicos, al\u00e9m de reduzir a express\u00e3o epitelial de p53 e Ki67, \n\nevidenciada atrav\u00e9s de imunohistoquimica22. Em estudos comparativos com filtro solar comum, o \n\nfotoprotetor associado \u00e0 fotoliase demonstrou maior redu\u00e7\u00e3o no grau de altera\u00e7\u00f5es moleculares \n\nrelacionadas \u00e0 fotoexposi\u00e7\u00e3o 23. \n\nPeelings qu\u00edmicos tamb\u00e9m podem ser utilizados no tratamento do campo de \n\ncanceriza\u00e7\u00e3o cut\u00e2neo, como peelings de m\u00e9dia profundidade de \u00e1cido glic\u00f3lico 70% ou solu\u00e7\u00e3o \n\nde Jessner e 5FU 5% em propilenoglicol, em sess\u00f5es quinzenais24. Peelings de solu\u00e7\u00e3o de \n\nJessner associada a \u00e1cido tricloroac\u00e9tico (ATA) 35% apresentam boa resposta dentro de 12 \n\nmeses de tratamento 25.  O ATA tamb\u00e9m pode ser utilizado e m concentra\u00e7\u00f5es mais altas, como \n\n50 e 70%, de forma pontuada nas QAs, sem tratar, entretanto, o campo de canceriza\u00e7\u00e3o em si. \n\nAl\u00e9m dos tratamentos acima, existem outros descritos, como diclofenaco s\u00f3dico, \n\nresiquimod, colchicina e a terapia fotodin\u00e2mica (TFD), esses dois \u00faltimos s\u00e3o objetos desse \n\nestudo e ser\u00e3o discutidos posteriormente. \n\nUm sum\u00e1rio de estudos cl\u00ednicos randomizados e controlados que empregaram dife rentes \n\nestrat\u00e9gias no tratamento das QAs est\u00e1 disposto na tabela 1.  \n\nNa Unesp de Botucatu, QAs s\u00e3o extremamente prevalentes e os tratamentos mais \n\nempregados s\u00e3o a crioterapia com nitrog\u00eanio l\u00edquido, 5FU e TFD.  \n\n  \n\n\n\n17 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\n \n\nTabela 1. Principais estudos sobre o tratamento de queratoses act\u00ednicas e do campo de canceriza\u00e7\u00e3o. \n\nAutor \n(refer\u00eancia) \n\nI nterven\u00e7\u00e3o \n\nN\u00famero de \n\npacientes (tipo \nde estudo) \n\nRegime Resultados \n\nHarvey et al \n(26) \n\nAcompanhamento 1034 (longitudinal) \nObserv a\u00e7\u00e3o por 12 \n\nmeses \nRedu\u00e7\u00e3o de 21% # \n\nT hompson et al, \n(21) \n\nFotoprotetor \nFPS 17 \n\n588 (controlado, \nrandomizado, \n\naberto) \n\nAplica\u00e7\u00e3o di\u00e1ria por \n6 meses \n\nC ontrole: placebo \n\nRedu\u00e7\u00e3o de 25% # \n\nC ontrole: redu\u00e7\u00e3o de 18% # \n\nCarducci et al, \n(23) \n\nFotoprotetor \nassociado \u00e0 \n\nfotoliase \n\n28 (randomizado, \ncontrolado, \n\naberto) \n\nAplica\u00e7\u00e3o di\u00e1ria por \n6 meses \n\nC ontrole: fotoprotetor \n\nRedu\u00e7\u00e3o de d\u00edmeros de ciclobutano \npirimidina (C PD) de 61%  \n\nC ontrole: redu\u00e7\u00e3o de C PD de 35%  \nRedu\u00e7\u00e3o de QAs hiperquerat\u00f3ticas \n\nem ambos os grupos \n\nKurwa et al, \n(27) \n\n5FU  5%  \n17 (randomizado, \n\ncontrolado, \naberto) \n\n2x  por dia por 3 \nsemanas \n\nC ontrole: TFD 5-ALA \n\u00fanica sess\u00e3o \n\nRedu\u00e7\u00e3o da \u00e1rea lesionada de 70% * \nTFD (controle): redu\u00e7\u00e3o da \u00e1rea \n\nlesionada 73% * \n\nSzeimies et al \n(9) \n\nImiquimod 5%  \n\n286 (duplo-cego, \ncontrolado, \n\nrandomizado, \nparalelo) \n\nU ma v ez ao dia, tr\u00eas \nv ezes por semana, \n\n16 semanas \nC ontrole: placebo \n\nC learance completo de QA: 57.1%  \nvs 2.2%  (placebo) \n\nC learance parcial de QA: 72.1%  vs \n4.3%  (placebo) \n\nWolf et al (28) \nDiclofenaco \ns\u00f3dico 3%  \n\n96 (duplo-cego, \ncontrolado, \n\nrandomizado) \n\n1x / dia por 90 dias \nC ontrole: placebo \n\nRecomendado filtro \nsolar em ambos os \n\ngrupos \n\nRedu\u00e7\u00e3o de 47% # \n\nC ontrole: redu\u00e7\u00e3o de 19% # \n\nEuvrard (20) Tretino\u00edna 0,5%  \n100 (duplo-cego, \n\ncontrolado, \nrandomizado) \n\n1x  ao dia por 90 dias \nC ontrole: placebo \n\nRedu\u00e7\u00e3o de 45% # \n\nC ontrole: redu\u00e7\u00e3o de 23% # \n\nAkar et al (29) C olchicina \n16 (randomizado, \naberto, pareado) \n\nC olchicina 1%  vs 0,5 \n2x / dia por 10 dias \n\nReav alia\u00e7\u00e3o: 6 \nmeses \n\nC olchicina 1% : redu\u00e7\u00e3o de 74% #   * \nC olchicina 0,5% : redu\u00e7\u00e3o de 78% #  * \n\nPariser et al (30) TFD \n80 (randomizado, \n\nduplo-cego) \n\nTFD-MAL 2 sess\u00f5es \ncom interv alo de 1 \nsemana. C ontrole: \nTFD com placebo \n\nC learance completo 89%  \nC ontrole: C learance completo 38%   \n\nFagihi (31) C olchicina \n70 les\u00f5es (duplo-\n\ncego, \nrandomizado) \n\nC olchicina 1%  gel 2x / \ndia por 6 semanas \n\nC ontrole: diclofenaco \n3%  gel \n\n50%  de redu\u00e7\u00e3o da m\u00e9dia  \ndo tamanho das les\u00f5es  \nem ambos os grupos* \n\n# Contagem de QAs; * p>0,05 = ns; TFD = Terapia fotodin\u00e2mica \n\n \n\nH\u00e1 poucos ensaios cl\u00ednicos na literatura com o uso de colchicina t\u00f3pica, e os \n\nencontrados apresentam um pequeno n\u00famero de participantes .  Al\u00e9m disso, n\u00e3o h\u00e1 nenhum \n\nestudo comparando a efic\u00e1cia da colchicina com a terapia fotodin\u00e2mica com aminolevulinato de \n\nmetila (MAL), o que justifica a import\u00e2ncia do projeto apresentado.  \n\n \n\n1.3 Colchicina \n\n \n\n\n\n18 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\nA colchicina, extra\u00edda da planta Colchicum autumale (Figura 4)32, \u00e9 uma droga muito \n\nantiga e de baixo custo, conhecida historicamente pela melhora em dores articulares e, por isso, \n\nprimariamente utilizada no tratamento da gota.  \n\n \n\n  \n\nFigura 4: Colchicum autumale (Bhat, 2009) e estrutura qu\u00edmica da colchicina (Grima?tre, 2000) \n\n \n\nA colchicina se liga \u00e0s prote\u00ednas microtubulares e interfere na fun\u00e7\u00e3o dos fusos \n\nmit\u00f3ticos. Com isso, inibe a prolifera\u00e7\u00e3o celular e a quimiotaxia de polimorfonucleares. Como \n\nefeitos colaterais, pode causar dor abdominal, n\u00e1useas, v\u00f4mitos, diarrei a, anemia apl\u00e1stica e \n\nagranulocitose.  Apresenta janela terap\u00eautica restrita e lenta elimina\u00e7\u00e3o (meia-vida de 14 a 30 \n\nhoras), atrav\u00e9s de elimina\u00e7\u00e3o renal e biliar33,34. O grau de absor\u00e7\u00e3o cut\u00e2nea \u00e9 desconhecido 35. \n\nNa dermatologia, a colchicina foi empregad a em diferentes indica\u00e7\u00f5es terap\u00eauticas, \n\ntanto na via sist\u00eamica ou t\u00f3pica, dentre elas: psor\u00edase vulgar, psor\u00edase pustulosa generalizada, \n\npustulose palmo plantar, vasculite de pequenos vasos, rea\u00e7\u00e3o tipo II da hansen\u00edase, doen\u00e7a de \n\nBeh\u00e7et, dentre outras35. \n\nA primeira descri\u00e7\u00e3o do uso da colchicina t\u00f3pica p ara QA foi em 1968 por Marshall36. O \n\nprimeiro ensaio cl\u00ednico foi realizado em 2000,  com a aplica\u00e7\u00e3o de colchicina 1% creme nas QAs, \n\npor at\u00e9 10 dias, quando efeitos colaterais como eritema, crostas e eros\u00f5es foram encontrados37. \n\nAt\u00e9 ent\u00e3o, poucos estudos foram realizados 29,31,36,37. \n\nA colchicina j\u00e1 foi estudada nas concentra\u00e7\u00f5es de 0,5% e 1% em gel, sem diferen\u00e7as \n\nestat\u00edsticas nos resultados e eventos adversos, com boa tolerabilidade.  Apresentou  redu\u00e7\u00e3o das \n\ntaxas de QAs em 77%, associada a satisfat\u00f3rio resultado est\u00e9tico p\u00f3s -tratamento, com \n\npossibilidade de eritema discreto ou hipopigmenta\u00e7\u00e3o 29.  Entretanto, faltam estudos que \n\nsistematizem a posologia e dura\u00e7\u00e3o do tratamento, bem como avalia\u00e7\u00f5es comparativas com \n\noutras drogas j\u00e1 consagradas no tratamento das QAs 31,32,33. \n\n \n\n\n\n19 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\n1.4 Terapia Fotodin\u00e2mica \n\n \n\nA TFD \u00e9 uma modalidade terap\u00eautica utilizada por diversas especialidades oncol\u00f3gicas, \n\nque consiste em induzir citotoxicidade  nas c\u00e9lulas proliferativas de um tumor atrav\u00e9s da emiss\u00e3o \n\nde uma fonte de luz e de localiza\u00e7\u00e3o dessa atividade por meio de um agente fotossensibilizante, \n\npodendo este ser oral ou t\u00f3pico 38-40. \n\nEm dermatologia, a TFD destina-se ao tratamento de les\u00f5es pr\u00e9 -malignas e de tumores \n\ncut\u00e2neos n\u00e3o-melanoma, como o carcinoma basocelular superficial e doen\u00e7a de Bowen (CEC in \n\nsitu).  Al\u00e9m de seu uso na dermatologia oncol\u00f3gica, a TFD tamb\u00e9m \u00e9 utilizada no tratamento de \n\ndermatoses inflamat\u00f3rias como psor\u00edase, doen\u00e7a de Darier, sarcoidose e necrobiose lipo\u00eddica41. \n\nPara sua execu\u00e7\u00e3o, o paciente dever\u00e1 ser exposto previamente a um agente t\u00f3pico \n\nfotossensibilizante. Os mais utilizados s\u00e3o o \u00e1cido 5-delta aminolevun\u00edlico (ALA) e seu derivado \n\nlipof\u00edlico, o metil \u00e9ster do ALA (MAL) (Figura 5). Este \u00faltimo \u00e9 mais empregado por se utilizar de \n\nmecanismos de absor\u00e7\u00e3o n\u00e3o -satur\u00e1veis, com consequente maior penetra\u00e7\u00e3o e maior absor\u00e7\u00e3o \n\npelas c\u00e9lulas neopl\u00e1sicas41,42. \n\n \n\n \n\nFigura 5: Aminolevulinato de metila (Pharmazeutische zeitung online. Methyl-(5-amino-4-oxopentanoat) \n\nMetvix\u00ae Creme (Galderma Laboratorim) \n\nDispon\u00edvel em: http://www.pharmazeutische-zeitung.de/index.php?id=185 \u2013 acesso em 29/05/17) \n\n \n\nO MAL \u00e9 precursor da protoporfirina IX, que gera esp\u00e9cies ativas de oxig\u00eanio nos \n\nqueratin\u00f3citos displ\u00e1sicos, que s\u00e3o metabolicamente mais ativos, caso haja exposi\u00e7\u00e3o oriunda \n\nde uma fonte de luz com comprimento de onda adequado42. \n\nO MAL \u00e9 administrado via t\u00f3pica, na formula\u00e7\u00e3o em creme a 16%, e mantido sob \n\noclus\u00e3o durante tr\u00eas horas antes do procedimento.  Passado esse per\u00edodo, o paciente \u00e9 \n\nsubmetido \u00e0 exposi\u00e7\u00e3o de uma fonte de luz, que pode ser de tr\u00eas tipos: l\u00e2mpadas de amplo \n\nespectro, l\u00e2mpadas de diodo e lasers 40. \n\nhttp://www.pharmazeutische-zeitung.de/fileadmin/arzneistoffe/methyl5amino4oxopentanoat.wrl\nhttp://www.pharmazeutische-zeitung.de/fileadmin/arzneistoffe/methyl5amino4oxopentanoat.wrl\nhttp://www.pharmazeutische-zeitung.de/index.php?id=185\n\n\n20 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\nAs l\u00e2mpadas de diodo s\u00e3o fontes de luz de alta pot\u00eancia, que trabalham em faixas \n\nrestritas de bandas de luz, podendo ser de luz azul ou vermelha38.  Fontes de luz azul ativam o \n\nMAL com intensidade maior que fontes de luz vermelha43,44, enquanto esta apresenta maior \n\npenetra\u00e7\u00e3o no tecido. No Departamento de Dermatologia da UNESP -Botucatu, a fonte utilizada \u00e9 \n\ndiodo emissor de luz vermelha (Figura 6). \n\n \n\n \n\nFigura 6: Aparelho Aktilite Galderma \u2013 Diodo emissor de luz vermelha (dispon\u00edvel em: \n\nhttp://www.galderma.se/Vara-produkter-/Produkter-ej-lakemedel/Aktilite - acesso em 29/05/17) \n\n \n\nNo per\u00edodo de absor\u00e7\u00e3o, o MAL \u00e9 demetilado a 5-ALA e este entra na cadeia de \n\nprodu\u00e7\u00e3o de protoporfirina IX, que se acumula nas c\u00e9lulas alteradas. Durante a emiss\u00e3o de luz, \n\na protoporfirina IX \u00e9 ativada. Essa ativa\u00e7\u00e3o leva o oxig\u00eanio  presente nos tecidos do estado de \n\nrepouso (ou forma triplet) \u00e0 forma ativa, de meia vida curta, denominada singlet.  Em decorr\u00eancia \n\nda presen\u00e7a do oxig\u00eanio singlet, as c\u00e9lulas passam a sofrer altera\u00e7\u00f5es de membrana (Figura 7 ), \n\no que prejudica a permeabilidade e o transporte de subst\u00e2ncias, al\u00e9m de causar toxicidade \u00e0s \n\norganelas citoplasm\u00e1ticas, induzindo as c\u00e9lulas neopl\u00e1sicas \u00e0 apoptose 40. \n\n \n\nhttp://www.galderma.se/Vara-produkter-/Produkter-ej-lakemedel/Aktilite\n\n\n21 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\n  \nFigura 7. Representa\u00e7\u00e3o esquem\u00e1tica T FD. (Fonte: adaptado de Piacquadio, 2004).   \n\n \n\n A TFD apresenta taxas de resposta de 81% para uma \u00fanica sess\u00e3o de TFD a 90% ap\u00f3s \n\nduas sess\u00f5es no tratamento das QAs, com efeitos adversos de curta dura\u00e7\u00e3o e moderada \n\nintensidade, al\u00e9m de resultados est\u00e9ticos satisfat\u00f3rios 30,44-46. \n\nAt\u00e9 o momento, h\u00e1 poucos ensaios cl\u00ednicos realizados com colchicina t\u00f3pica e somente \n\num estudo comparativo para tratamento para campo de canceriza\u00e7\u00e3o cut\u00e2neo 31, justificando a \n\nimport\u00e2ncia deste estudo. \n\n1.5 Refer\u00eancias \n\n1. Sch mitt JV, M io t HA.  Actinic keratosis: a  clin ica l and epide miolog ica l revision. An Bras Der ma tol \n2012;87:425-34. \n\n2.  Salasche SJ. Ep ide miology o f actinic kerato sis and squa mou s ce ll carcin o ma. JAm Acad Der ma tol.  \n2000;42:4-7. \n\n3. Moy RL. Clinica l presen ta tion o f actinic kera to ses and squa mou s ce ll car cino ma. J Am Acad Der ma tol \n\n2000;42:8-10. \n4. Olse n EA, Aberne thy ML, Kulp-Shor ten C e t al. A doub le-blind, vehicle-con trolled study evalua ting  \n\nma soproco l cream in the  trea tmen t o f a ctin ic  kera to ses on the head  and  neck. J Am Acad  Der ma tol 1991;  \n\n24: 738\u201343. \n5. Ianhez M,  Ju nior LFFF, Baga tin E, e t al.  The reliability o f coun ting a ctin ic kera to sis. Arch  Der ma tol Res \n\n2013; 841\u20134.  \n6. Torezan LA, Festa-Ne to C. Cu taneous field canceriza tion: clinical, histopa tho logical and therapeu tic \n\naspects. An Bras Dermatol 2013; 88: 775-86. \n7. Slaugh ter DP, Sou thw ick H W, Sme jka l W. Fie ld can ceriza tion in oral stra tified sq ua mous ep ithe liu m;  \n\nclinical implications of multicentric origin. Cancer 1953; 6: 963-8. \n\n8. Szeimies RM,  Torezan L, Niwa A, et al. C lin ica l, histopa tho logical an d immuno histoche mica l assessmen t \nof human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150 -9. \n\n9. Ulrich C. Topical treatment of field cancerization. Cancer Treat Res 2009; 146: 439 -46. \n\n\n\n22 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\n10. Kirby JS, Scharnitz T, Seiverling EV, e t al. Actinic kera tosis clinical practice guidelines: an appraisal o f \n\nquality. Dermatol Res Pract. 2015;2015:456071. \n11. Ianhez M,  Mio t HA,  Baga tin E. Liquid  nitrogen  for the trea tme n t o f actinic kerato sis: a  lon gitud inal \n\nassessment. Cryobiology  69.1 (2014): 140-3. \n\n12. Freeman RG, Knox JM, Hea ton CL. The trea tmen t o f skin cancer. A sta tistica l study o f 1,341 skin tu mors \nco mparing results ob taine d with irradia tion, surgery, and curetta ge fo llowed by electrode sicca tion.  Cancer. \n1964; 17:535\u20138. \n\n13. Zane C, Facch ine tti E, Ro ssi MT, et  al.  Cryotherapy is pre ferable to ab la tive CO2  la ser for the  treatmen t o f \n\nisola ted actinic keratose s o f the  face and scalp:  A rando mized  clinical trial. Br J Der ma to l. 2014;  170(5): \n1114-21.  \n\n14. Sega tto MM, Dornelle s SI, Silveira VB, e t a l. Co mpara tive study o f actinic kera tosis trea tmen t with 3% \n\ndiclofenac sodium and 5%  5-fluorouracil. An Bras Dermatol 2013; 88: 732-8. \n15. Hagele TJ, Levender MM,  Davis S A, e t a l. Pra ctice trends in the trea tmen t o f a ctin ic kera tosis in the  United  \n\nSta tes: 0.5%  fluorouracil and co mbina tion cryoth erapy plus fluorouracil are underused despite evidence o f \n\nbenefit. J Cutan Med Surg 2012; 16: 107-14. \n16. Martin G. Prospective, case-based a sse ssmen t o f sequ en tia l therapy with to pical Fluorouracil crea m 0.5% \n\nand ALA-PDT for the treatment of actinic keratosis. J Drugs Dermatol 2011; 10: 372-8. \n17.  Tester man TL, Gerster JF, I mber tson LM, e t a l. Cyto kine  indu ction by the immuno mod ula tors imiqu imod  \n\nand S-27609. J Leukoc Biol 1995; 58: 365\u201372. \n18. Lebwohl M,  Swan son N,  Anderso n LL,  e t a l. Ing enol Mebu ta te  Ge l for Actinic Kera to sis. N  Engl J Med.  \n\n2012; 14; 366(11): 1010\u20139. \n\n19. Ianhez M, Fle ury LF, Jr., Mio t HA, e t al. Re tinoid s for prevention and trea tmen t o f a ctin ic kera tosis. An Bras \nDermatol 2013; 88: 585-93. \n\n20. Euvrard S, Verschoore M, Touraine JL, e t al. Topical re tinoid s for warts and kera to sis in transplan t \n\nrecipients. Lancet. 1992; 340: 48-9. \n21. Thomp son SC, Jo lley D, Marks R. Redu ction o f solar kerato ses by regular sun screen u se. N Eng l J Med  \n\n1993; 329: 1147-51. \n22. Puviani M,  Barce lla  A, M ila ni M.  Effica cy o f a pho tolyase-ba sed device in the  trea tmen t o f can ceriza tion  \n\nfield in pa tien ts with a ctin ic kera to sis and non-me lano ma skin cancer. G I tal Der ma tol Ve nereol 2013;148:  \n693-8. \n\n23. Carducci M, Pavone PS, De Marco G, e t al. Co mpara tive effe cts o f sun screen s alone vs sun screens p lus \n\nDNA repair enzy mes in pa tien ts with a ctin ic kera tosis:  clinical and mo lecu lar find ings fro m a 6- mon th,  \nrandomized, clinical study. J Drugs Dermatol 2015; 14(9): 986-90. \n\n24. Witheiler DD, Lawrence N, Cox SE, e t al. Long- ter m e fficacy and sa fe ty o f Je ssner' s so lu tion and 35%  \n\ntrichloroace tic acid vs 5%  fluorouracil in th e treatmen t o f wide spread facial a ctin ic kera tose s. Der ma tol \nSurg. 1997; 23(3): 191-6. \n\n25. Baga tin E, Teixeira S P, Hassun KM, e t a l. 5-Fluorouracil superficial peel for multiple a ctin ic kera toses. In t J \nDermatol. 2009; 48(8): 902\u20137. \n\n26. Harvey I, Frankel S, Marks R e t al.  Non-melano ma  skin  can cer and  so lar kerato ses.  I.  Me thods and  \ndescriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74:1302-7. \n\n27. Kurwa HA, Young-Gee AS, Seed P, e t al . A rando mized paired co mp arison o f pho todyna mic therapy and \n\ntopical 5-fluorouracil in the treatment of actinic keratoses. J Acad Dermatol 1999: 41 (3); 414-18. \n28. Wo lf JE, Taylor JR, Tsch en E, e t  a l. Topical 3.0%  diclo fenac in 2.5%  hyaluronan gel in  the trea tmen t o f \n\nactinic keratoses. Internat J Dermatol 2001; 40 (11); 709-13. \n\n29. Akar A, B\u00fclen t Ta?tan H, Erbil H  e t al.  E ffica cy and sa fe ty a sse ssmen t o f 0.5%  and 1%  colch icine cream in  \nthe treatment of actinic keratoses. J Dermatolog Treat. 2001; 12(4): 199 \u2013203. \n\n30. Pariser DM, Lowe NJ, Stewart DM, e t al. Pho to dynamic therapy with to pical me thyl a mino levulin a te for \nactin ic kera tosis: Re sults o f a prospe ctive rando mized multicen ter tria l. J A mer A cad Der ma to l 2003;  48(2): \n\n227-32. \n31. Faghihi G, Elahipo or A, Iraji F, et al. Topical colchicine gel versus d iclo fenac sodiu m ge l for the trea tmen t \n\nof actinic keratoses?: a randomized , double-blind study. Adv in Med; 2016:6\u201311. \n\n32. Konda C, Rao AG. Colchicine in dermatology. Indian J Dermatol Venereol Leprol 2010; 76: 201 -5. \n33. Falkson G. Some aspects of the use of cytostatic drugs in dermatology. S Afr Med J 1966; 40: 339 -42. \n34. Guy RH, Hadgraft J. Physico che mical aspe cts o f percu taneo us pene tra tion and its enhance men t.  Phar m \n\nRes. 1988; 5(12): 753-8. \n35. Sullivan TP, King LE, Jr., Boyd AS. Colchicine in dermatology. J Am Acad Dermatol 1998; 39: 993-9. \n36. Marshall J.Trea tmen t o f solar kera tosis w ith top ica lly app lied cyto sta tic agen ts. Br J Der ma tol 1968;80:54 0 -\n\n2. \n\nhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Witheiler%20DD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=9145962\nhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Lawrence%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=9145962\nhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Cox%20SE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=9145962\nhttps://www.ncbi.nlm.nih.gov/pubmed/9145962\nhttps://www.ncbi.nlm.nih.gov/pubmed/9145962\nhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Guy%20RH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=3247284\nhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Hadgraft%20J%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=3247284\nhttps://www.ncbi.nlm.nih.gov/pubmed/3247284\nhttps://www.ncbi.nlm.nih.gov/pubmed/3247284\n\n\n23 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                      Revis\u00e3o de Literatura  \n\n \n\n37. Grima ?tre M, Etienne A, Fathi M. Top ica l Colchicine Therapy for Actinic Kera to ses. Der ma to logy 2000; 200:  \n\n346-8. \n38. Wiegell SR. Update on photodynamic treatment for actinic keratosis. Curr Probl Dermatol 2015; 46: 122 -8. \n39. Morton C A, M cKenna  KE,  Rhode s LE.  Gu idelines for top ica l pho todynamic therapy: upda te.  Br J Der ma tol \n\n2008; 159: 1245-66. \n40. Torezan L, Niwa AB, Ne to CF. Pho todyna mic therapy in derma tology: basic prin cip les. An Bras Der ma tol  \n\n2009; 84: 445-59. \n41. Mitra A, Stab les GI. Topica l photodynamic therapy for non-cancerou s skin cond ition s. Pho todiagnosis \n\nPhotodyn Ther 2006; 3: 116-27. \n42. Braathen LR, Mor ton CA, Basse t-Seguin N, e t al. Pho todyna mic therapy for skin field ca nceriza tion: an  \n\nin ternationa l con sensu s. In terna tion al So cie ty for Pho todyna mic Therapy in Derma tolo gy. J Eur Acad  \n\nDermatol Venereol 2012; 26: 1063-6. \n43. Kim HS, Yoo JY, Cho KH, e t a l. Topica l pho todyna mic therapy using in tense pu lsed ligh t for trea tmen t o f \n\nactinic keratosis: clinical and histopathologic evaluation. Dermatol Surg 2005; 31: 33 -6. \n\n44. Piacqu adio DJ, Chen DM, Farber HF et al. Photodyna mic therapy with a minolevulinic acid top ica l solu tion  \nand visible  blue  ligh t in the trea tmen t o f multiple a ctin ic kera tose s o f the  face  and  scalp:  investiga tor -\nblinded, phase 3, multicenter trials. Arch Dermatol 2004 Jan;140(1):41-6. \n\n45. Hsi RA, Rosen tha l DI, Gla tstein E. Ph o todyna mic therapy in trea tmen t o f can cer. Drugs 1999; 57(5): 725-\n\n34. \n46. Tarsted t M, Ro sdahl I,  Berne B, e t al.  A  rando mized multicen ter study to  co mpare two trea tmen t regimens \n\nof top ica l me thyl a mino levulina te (Metvix) -PDT in actin ic kera to sis o f the face and sca lp. Acta Derm \n\nVenereol 2005; 85: 424\u20138. \n \n\n \n\n\n\n24 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                          Objetivos \n\n \n\n2.  OBJETIVOS \n\n \n\n \n\nOBJETIVO GERAL \n\nAvaliar a efic\u00e1cia e seguran\u00e7a do creme de colchicina 0,5%  duas vezes por dia por 10 dias \n\nversus TFD sess\u00e3o \u00fanica com cloridrato de aminulevulato de metila (MAL-TFD) no tratamento do \n\ncampo de canceriza\u00e7\u00e3o cut\u00e2neo em pacientes com m\u00faltiplas queratoses act\u00ednicas dos \n\nantebra\u00e7os ap\u00f3s 60 dias. \n\n \n\nOBJETIVOS ESPEC\u00cdFICOS \n\n1. Avaliar a melhora cl\u00ednica das QAs atrav\u00e9s da quantifica\u00e7\u00e3o da contagem de QAs, \n\ngradua\u00e7\u00e3o de sua intensidade e escore  de gravidade de QAs entre os tratamentos \n\nrealizados; \n\n2. Avaliar o aspecto do campo de  canceriza\u00e7\u00e3o atrav\u00e9s da escala de fotoenvelhecimento \n\ndos antebra\u00e7os, entre os tratamentos realizados; \n\n3. Avaliar a modifica\u00e7\u00e3o do perfil de atipia histol\u00f3gica do campo de canceriza\u00e7\u00e3o entre os \n\ntratamentos atrav\u00e9s do escore KIN; \n\n4. Avaliar melhora da espessura epitelial entre os tratamentos; \n\n5. Avaliar a modifica\u00e7\u00e3o da express\u00e3o de p53 e Ki67 do campo de canceriza\u00e7\u00e3o entre os \n\ntratamentos; \n\n6. Avaliar a tolerabilidade atrav\u00e9s da prefer\u00eancia subjetiva e efeitos adversos dos \n\ntratamentos.\n\n\n\n \n25 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\n3. MANUSCRITO \n\n \n\n \n\nFormato: British Journal of Dermatology \n\n \n\nSection: Original article \n\n \n\nTitle: Efficacy and safety of colchicine 0.5% cream versus photodynamic therapy (methyl \n\naminolevulinate) in the treatment of actinic keratosis and skin field cancerization of the forearms: \n\na randomised controlled trial. \n\n \n\nRunning head: Colchicine versus photodynamic therapy in skin field cancerization.  \n\n \n\nCounting: words = 3021; tables = 3; figure = 1 \n\n \n\nAuthors: AC Miola1, EF Roio1, TRR Lima2, JV Schmitt1, LPF Abbade1, HA Miot1 \n\n1 Department of Dermatology and Radiotherapy, FMB -UNESP, Botucatu, SP, Brazil. \n\n2 Department of Pathology, UNESP-Botucatu, S\u00e3o Paulo, Brazil \n\n \n\nCorresponding author:  \n\nAnna Carolina Miola \n\nDepartamento de Dermatologia e Radioterapia \n\nBotucatu Medical School - Unesp \n\nAv. Prof. M\u00e1rio Rubens Guimar\u00e3es Montenegro, s/n \n\nRubi\u00e3o J\u00fanior, Botucatu/SP, Brasil, 18618-970 \n\nMail address: anna_fmrp@yahoo.com.br \n\n  \n\nmailto:anna_fmrp@yahoo.com.br\n\n\n \n26 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nWhat\u2019s already known about this topic? \n\n? Photodynamic therapy is a known treatment for actinic keratosis and skin field \n\ncancerization \n\n? There are trials with topical colchicine demonstrating  its efficacy in the treatment of \n\nactinic keratoses  \n\n? There are no studies comparing colchicine with photodynamic therapy for the treatment \n\nof actinic keratosis and skin field cancerization \n\nWhat does this study add? \n\n? Topical colchicine decreases the activity of skin field cancerization \n\n? Colchicine doesn\u2019t differ from photodynamic therapy in the treatment of skin field \n\ncancerization \n\n \n\n  \n\n\n\n \n27 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nSummary \n\n \n\nBackground: Skin field cancerization (SFC) is an epithelial zone with genomic alterations induced by \n\nUVR, and actinic keratosis (AK) is a sign of its activity. Se veral treatments may reduce the incidence of \n\nAK. Photodynamic therapy with methyl aminolevulinate (PDT -MAL) and topical colchicine were reported \n\nas effective in AK count reduction. \n\nObjective: Evaluate efficacy and safety of colchicine 0.5% cream versus PDT-MAL in the treatment of AK \n\nand SFC. \n\nPatients and methods: Randomised, open, intrasubject controlled clinical trial: 36 participants, with 3-10 \n\nAK in each forearm, treated with colchicine (COL) cream (b.i.d., 10 days) or a single session of PDT -MAL, \n\nthey were reassessed after 60 days. Clinical evaluation was performed by AK count, forearm photoaging \n\nscale (FPS), AK degree (AKD) and AK severity score (AKSS). T he subjects were biopsied in both central \n\nforearms and histopathological evaluation was performed through KIN assessment, epithelial atrophy and \n\nimmunohistochemistry (p53 and Ki67).  \n\nResults: 50% were males, mean (sd) age of 70.9 (8.6) years and predominance of phototypes I and II \n\n(89%). T otal clearance occurred in 6 (17%) of COL and 7 (19%) of PDT-MAL (p=0.76); partial clearance \n\nwas 44% in COL and 67% in PDT-MAL (p=0.07). COL and PDT-MAL FPS (-6% vs -6%), AKSS (-65% vs -\n\n73%) and AKD (-45% vs -40%) were reduced (p<0.01). KIN normalized in 28% of MAL-PDT  patients and \n\n20% in COL. Epithelial atrophy reduced after treatment (p<0.01); Ki67 reduced 15% in COL and 9% in \n\nPDT -MAL (p<0.01). There was no difference between groups for any of the variables above (p>0.07).  p53 \n\nwas reduced 27% in COL and increased 4% in PDT -MAL (p<0.05). Mild or moderate adverse effects were \n\nobserved in 75% of COL patients and 69% of PDT -MAL. \n\nConclusion: Colchicine 0.5% cream and PDT -MAL are effective and safe in the treatment of SFC. \n\n \n\nThis study was recorded in the Brazilian Reg istry of Clinical Trials (REBEC no. RBR-8y3sj9). \n\n \n\nKeywords: Actinic keratosis, Chemoprevention, Colchicin, Dermatology, Field \n\ncancerization, Oncology, Photochemoterapy, Photodynamic therapy, Squamous cell carcinoma.  \n\n  \n\n\n\n \n28 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nIntroduction \n\nActinic keratosis (AK) is an atypical keratinocyte proliferation that can evolve to a \n\nsquamous cell carcinoma (SCC) in up to 20% of the cases within ten years1,2. \n\nField cancerization is an area with genomic alterations induced by ultraviolet radiation \n\n(UVR). This concept was described in 1953 by Slaughter in oral squamous cell carcinoma, as an \n\napparently normal tegument area with subclinical and multifocal changes, composed of \n\ngenetically altered cells3. The skin field cancerization (SFC) concept suggests that the apparently \n\nnormal skin adjacent to AKs is the basis for clonal expansion of genetically altered cells, which \n\ncan explain the eruption of new AK, skin cancer (non melanoma) in same area as well as the \n\nlocal recurrence of neoplasms considered completely excised by histopathological analysis 4,5. \n\nThe treatment for SFC has been extensively studied, because it can lead to reduce the \n\nincidence of AK and SCC in high risk patients 6.  Many treatment modalities for SFC are available, \n\ne.g. 5-fluorouracil (5FU)7, ingenol mebutate 8, imiquimod9, tretinoin10, diclofenac11 and \n\nphotodynamic therapy12. \n\nColchicine is an antimitotic agent, extracted from the plant Colchicum autumale13, which \n\nbinds to microtubular proteins and interfere with the activity of mitotic spindles14, interrupting \n\nmitosis at metaphase. Colchicine has been initially studied at concentration of 1% gel, twice daily, \n\nwith adverse events reported after 10 days of use. It disclosed a significant reduction of AK \n\ncounting15. Topical colchicine at 0.5% and 1% gel were studied in treatment of AKs, and showed \n\na similar reduction up to 77% in AK counting, associated with satisfactory aesthetic results and \n\nlow adverse events16. \n\nPhotodynamic therapy (PDT) is a therapeutic modality applied by several oncological \n\nspecialities17,18.  PDT induces cytotoxicity in the proliferative cells through the emission of a light \n\nsource after application of a photosensitizing agent (e.g. methy l aminolevulinate \u2013 MAL).  A single \n\ntreatment with PDT-MAL shows response rates up to 70-90% in the counting of AK. The adverse \n\neffects have short duration and they were of moderate intensity, as well as the aesthetic results \n\nwere satisfactory19. To date, there is no study comparing colchicine with photodynamic therapy in \n\nthe treatment of AK. \n\nThe purpose of this study was to evaluate the efficacy and safety of 0.5% colchicine \n\ncream, twice a day for ten days, versus MAL-PDT, single session, on field  cancerization \n\ntreatment in patients with multiple AK, by AK count, AK clinical degree and a score of AK severity. \n\nThe secondary objectives were: evaluate the aspect of forearms by a photoaging scale 20, the \n\n\n\n \n29 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nhistological atypia assessed as the keratinocyte intraepithelial neoplasia (KIN)21, epithelial \n\natrophy, p53 and Ki67 expression22. Moreover, the adverse effects were observed, as the \n\npreference and tolerability of the treatments.  \n\n \n\nPatients and methods \n\nPATIENTS \n\n Fourty outpatients from a public dermatologic clinic at Unesp Medical School (Botucatu-\n\nSP, Brazil) over the age of 18 years-old, both sexes, with the clinical diagnosis of fore arms AK \n\n(three to ten lesions) and without treatment to AK (except for sunscreen) for at least six months \n\nwere enrolled in this study. Thirty six subjects of this group were randomized after signing \n\ninformed consent (Anexo 1). \n\n The exclusion criteria were: extensive skin diseases affecting the forearms, current \n\nclinical diagnosis or evidence of any medical condition that exposes patient to increased risk, \n\ninterfere with safety or efficacy of proposed treatment; presence of hypersensitivity or allergy to \n\nthe substances under study, use of  topical or systemic immunosuppressive drug, oral retinoid, \n\nand other topical treatments (corticosteroids, anti-inflammatory drugs, retinoids), \n\nimmunosuppression, coagulation disorders, pregnancy suspected or confirmed or women breast-\n\nfeeding. \n\nSTUDY DESIGN \n\n This was an open, arm-randomised, intrasubject controlled clinical trial in which thirty six \n\npatients were treated with colchicine cream or MAL-PDT in each forearm. \n\nThis study was approved by the institutional board review (no. 1.356.401) and registered \n\nin the Brazilian Registry of Clinical Trials (REBEC no. RBR-8y3sj9). \n\nSTUDY OUTCOMES \n\n Primary outcome: reduction in AK count of the forearms 60 days after treatment with \n\nMAL- PDT or colchicine. \n\n Secondary outcome: The proportion of total AK clearance and partial (-50%) clearance of \n\nAK counting, reduction of activity of SFC aspect between the treatments analyzed by AK score, \n\nAK grades, AK severity score and the forearm photoaging scale; reduction of the histological \n\natypia assessed through the KIN score and its normalization (KIN=0), the epithelial atrophy and \n\nthe modification of p53 and Ki67 expression. \n\nPROCEDURES \n\n\n\n \n30 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\n The study units of analysis were each forearm in which treatment was randomised to the \n\ngroups named as MAL-PDT and colchicine (COL). \n\n In COL group, whole forearms were treated with colchicine 0.5% cream twice a day for \n\n10 days, provided by a compounding pharmacy.  In MAL-PDT, AK were curetted and the forearm \n\noccluded with methyl aminolevulinate 16% (Metvix\u00ae, Galderma Inc.) for three hours with PVC film \n\nand aluminum foil23, and after occlusion whole forearm has received one PDT session, with a \n\nlight emitting diode (LED) of 630nm wavelength (Aktlite \u00ae, Galderma Inc) at a distance of five to \n\neight centimeters from treated surface , for eight minutes, administered by the same researcher \n\n(ACM).  \n\n Each patient was followed for 60 days and instructed to apply in the  forearms a broad \n\nspectrum (UVA and UVB) sunscreen SPF 30 (Nivea Sun\u00ae, Beiersdorf Inc.) three times along the \n\nday. \n\n AK diagnosis was based on clinical and dermoscopic evaluation of a certified \n\ndermatologist. The areas of AK counting were delimited from the antecubital fossa to radiocarpal \n\nand radioulnar joints and biopsies were made in central region of each forearm, in an area \n\nwithout visible AKs or another cutaneous lesion. \n\nParticipants were assessed at: T0 for inclusion, randomization, clinical evaluation (AKs \n\ncount, AK grades, severity score of AK, photoaging scale), skin biopsy (bilateral) and the \n\ntreatment onset; at T15 for assessment of adverse effects and preference; at T60 for clinical \n\nevaluation (AKs count, AK grades, severity score of AK, photoaging scale) and bilateral skin \n\nbiopsy (figure 1). \n\nThe AK severity score was developed for this study (under validation-Anexo 4) and it \n\nallowed the evaluation of the intensity of the AKs present in skin. Its value was calculated by an \n\nindex: (E+H+I)*D, of each AK. In this equation, E is erythema, H is hyperkeratosis, I is infiltration \n\nand D is diameter. The results of each AK are s ummed, resulting in a score of each forearm.  \n\nThe AK were classified into three grades: Grade I (visible and slightly palpable), Grade II \n\n(visible and palpable) and Grade III (clearly visible and hyperkeratotic). Groups were compared \n\nafter an individual standardization of AK clinical severity as the Grade I AK were added to Grade \n\nII x 2 and the Grade III x 324. \n\n The photoaging scale evaluated the skin chronically exposed to the sun through the \n\nfollowing aspects: presence of superficial actinic keratoses, presence of hypertrophic actinic \n\n\n\n \n31 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nkeratoses, wrinkles, lentiginosis, visible purple, starred atrophic scars, loss of elasticity and \n\nelastosis, on a scale ranging from 0 to 19220. \n\n \n\n \n\nFigure 1: Study Design. CONSORT flow chart. \n\n \n\n \n\nSPECIMEN PROCESSING \n\nThe skin biopsies were fixed in 10% buffered formalin, embedded in paraffin blocks and \n\nsubmitted to histological sections of 4?m and stained by hematoxylin-eosin for histopathological \n\nevaluation of KIN score (Keratinocyte Intraepithelial Neoplasia) and epithelial atrophy. KIN \n\nclassification is a way to classify the intensity of keratinocytes atypia by its presence in \n\nepidermis25. KIN I has focal atypia, with depolarization at basal stratum, or the lower third of \n\nkeratinocytes; KIN II has depolarization at spinosum-granulosum strata; KIN III has depolarization \n\nin all epidermal strata.  Epithelial atrophy was measured counting stacked keratinocytes in \n\n\n\n \n32 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nepidermis (basal to granulous strata-epithelial layers). The assessment of KIN grade and \n\nepidermal atrophy were  blinded to the groups of treatment. \n\nFor immunohistochemistry, histological sections of 4?m thickness were mounted on \n\nsilanized slides (Sigma Chemical Corporation, Saint Louis, MO, USA) and subjected to \n\nimmunohistochemical staining for detection of Ki67 (Cell Sig. Tech., Inc., Danvers, MA, USA, \n\nmouse mAb IgG1, #9449) or p53 (Cell Sig. Tech., Inc., Danvers, MA, USA, mouse mAb Ig2b, \n\n#48818). After sections deparaffinization and rehydration was performed the endogenous \n\nperoxidase blockade with 3% H2O2 (Din\u00e2mica\u00ae Ltda, Diadema, SP, BRA) followed by heat-\n\ninduced antigen retrieval and protein blockade by treatment with milk. The sections were then \n\nincubated overnight at 4\u00b0C with the primary antibody diluted 1:300 or 1:150 for the Ki67 and p53 \n\nrespectly. Signal amplification was performed by biotin-free polymer detection system using the \n\nMACH 4\u00ae universal HRP-Polymer kit (Biocare Medical, Pike Lane Concord, CA, USA) according \n\nto the manufacturer's instructions. Lastly, 3-3' diaminobenzedine (DAB Substrate kit, Vector \n\nLaboratories, Burlingame, CA, USA) was used as a chromogenic substrate and the sections were \n\ncounterstained with Harris hematoxylin. Histological sections of mammary carcinoma were used \n\nas a positive control. \n\nThe epithelial expression of p53 and Ki67 was evaluated (T0 and T60) from the \n\nHSCORE, calculated in a central field  (objective 40x) of the epithelium26. The nuclei were \n\ncategorized individually according to staining as strong, medium, weak and stain-free, in order to \n\ndetermine the HSCORE. Manual counting of stained nuclei was performed by a researcher \n\nblinded to sample origin. HSCORE is a method for assessing the extent of nuclear \n\nimmunoreactivity, applicable to steroid receptors. The calculus of score is: 3x the percentage of \n\nstrongly staining nuclei + 2x the percentage of moderately staining nuclei + 1x the percentage of \n\nweakly staining nuclei, giving a range from 0 to 300. \n\nRANDOMIZATION AND BLINDING \n\nSubjects were eligible after clinical evaluation and included by convenience. Their \n\nforearms were randomized by computer simulation (block randomization) for treatment with \n\ncolchicine 0.5% cream, or MAL-PDT (Anexo 3). Inclusion was proceeded consecutively, by \n\nconvenience to the scheduled patients in the dermatologic clinic. This study was blinded only to \n\nthe histopathological evaluation regarding the treatment group (COL-MAL-PDT) and phase (T0-\n\nT60). \n\nSTATISTICAL ANALYSIS \n\n\n\n \n33 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nAll participants included in study and randomized were part of ITT group (intention to \n\ntreat)27. Data analysis were performed for ITT population28 and the dropouts were imputed as the \n\nlast visit outcomes (LOCF)29.  \n\nCategorical variables were represented by their percentages. Continuous variables were \n\nassessed for normality using the Shapiro -Wilk test and represented by means and standard \n\ndeviations or medians and quartiles (p25-p75), if indicated 30.  \n\nAK counting, AK grade, AK severity scale, forearms photodamage scale and the analysis \n\nof the histopathologic data were compared according to time and  to the groups (over time) by \n\nlinear mixed-effects model with robust covariance matrix and probability adjustment for each \n\ndistribution.  Post-hoc analysis was performed by sequential Sidak procedure.  \n\nData were tabulated in Microsoft Excel 2013, and statistical analysis were performed in \n\nSPSS 22.0.  Two-tailed p value&lt;5% was set as significant31. \n\nThe sample size was dimensioned in order to detect a reduction difference of more than \n\n10% between the groups and standard deviation of the equivalent differences. The power of 0.9, \n\nalpha of 0.05, and dropout of 10% were adopted, resulting in 36 patients (72 forearms)32. \n\n \n\nResults \n\nPATIENTS \n\n Between May 2016 and March 2017, 40 patients were eligible, of whom 36 were \n\ntreated with MAL-PDT or COL in each forearm, after randomization (figure 1). Only one subject \n\nwas not present at the final (T60) evaluation (dropout) due to the impossibility to contact her after \n\nseveral attempts. \n\n Pretreatment AK counting , AK grades, photoaging scale or AK severity did not differ \n\nbetween the groups (p>0.28). The main demographic characteristics of participants are disclosed \n\nin table 1. \n\n  \n\n\n\n \n34 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\n \n\nTable 1: Main demographics and baseline characteristics of patients (n=36). \n\nAge(years)*mean (sd) 70.9 (8.6) \n\nSex, n (%)  \n\n  Male 18 (50) \n  Female 18 (50) \n\nFitzpatrick skin phototype, n (%)  \n\n  I 11 (30.5) \n\n  II 21 (58.4) \n\n  III 4 (11.1) \n\nChronic sun exposure, n (%) 33 (92) \n \n\n  \n\n\n\n \n35 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nEFFICACY \n\n AK count was reduced in 45% and 40% in COL group and MAL-PDT group, respectly. \n\nBoth groups disclosed reductions (p<0.01) at all endpoints regarding the time of follow-up (table \n\n2). There was a reduction of AK severity score in 65%, photoaging scale in 6%. In MAL-PDT \n\ngroup, there was found a reduction of AK severity score (73%) and photoaging scale (6%). No \n\ndifferences were found between the groups in any tested variable (p?0.24). \n\n Total clearance occurred in 6 (17%) of COL group and 7 (19%) of MAL-PDT group \n\n(p=0.76).  Partial (>50%) clearance was achieved by 16 (44%) of COL forearms and 24 (67%) \n\nMAL-PDT (p=0.07). \n\n At histopathologic analysis, epithelial thickness reduced after 60 days of treatment \n\n(table 2) and was observed regularization of KIN of 20% in COL group and 28% in MAL-PDT \n\ngroup. In Ki67 HSCORE analysis, there was a reduction of 15% in COL and 9% in MAL-PDT. \n\nThese results were significant after 60 day s of treatment (p<0.001), but without difference \n\nbetween them (p>0.32). In p53 HSCORE, there was a reduction of 27% in COL and an increase \n\nof 4% in MAL-PDT, with statistical significance between the groups (p<0.05).  \n\n \n\nTable 2: Clinical and histopathological results of MAL-PDT  and COL (T 0 - T 60). \n\nVariables \nCOL \n\nT0 \nCOL \nT60 \n\nMAL-PDT \nT0 \n\nMAL-PDT \nT60 \n\np \n(time) \n\np \n(group*time) \n\nAK Count* \n5  \n\n(4-6) \n3 \n\n(1-4) \n6  \n\n(4-7) \n3 \n\n(1-4) \n<0.01 0.56 \n\nAK severity \n\nscore* \n\n5.1 \n\n(2.4-8.3) \n\n1.8 \n\n(0.5-3.3) \n\n4.7  \n\n(2.6-8.0) \n\n1.3 \n\n(0.4-2.4) \n<0.01 0.24 \n\nAK clinical \nsubtypes* \n\nI   2 (1-4) \n\nI I   3 (2-4) \nI I I   0 (0-0) \n\n1 (0-3) \n\n1 (0-2) \n0 (0-0) \n\n2 (0-4) \n\n3 (1-5) \n0 (0-0) \n\n1 (1-2) \n\n1 (1-3) \n0 (0-0) \n\n<0.01 0.46 \n\nPhotodamage \nscale* \n\n84  \n(73-103) \n\n79 \n(66-95) \n\n84 \n(70-105) \n\n80 \n(65-93) \n\n<0.01 0.87 \n\nPredominant \nKI N** \n\n \n\n    0     2 (6) \n  I     9 (25) \n\n  I I   25 (69) \n    I I I    0 (0) \n\n7  (20) \n12 (33) \n\n13 (36) \n4 (11) \n\n2  (6) \n8  (22) \n\n25 (69) \n1 (3) \n\n10 (28) \n9 (25) \n\n16 (44) \n1 (3) \n\n<0.01 0.35 \n\nEpithelial layers* 4 (3.5-4) 4 (4-4.5) 4 (3.25-4) 4 (4-4.5)&lt;0.01 0.58 \n\nKi67 HSCORE*** 49.4 (15.5) 41.9 (14.3) 50.0 (20.4) 38.0 (18.0)&lt;0.01 0.32 \n\np53 HSCORE* \n37.8 \n\n(23.2-63.2) \n27.7 \n\n(21.9-51.8) \n36.5  \n\n(17.4-55.9) \n38.3  \n\n(18.6-71.8) \n0.31&lt;0.05 \n\n* median (p25-p75); ** n (%); ***mean(sd) \n\n  \n\n\n\n \n36 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nSafety and tolerability \n\nThere were adverse events (AE) reported in both groups. In COL, 27 patients (69%) \n\nrelated AE, versus 24 (67%) in MAL-PDT.  Most of AE were mild (69%). No serious AEs were \n\nreported. In MAL-PDT group, the most AE reported was erythema and crusts, in 2% of the \n\npatients only, followed by peeling (1%) and edema, with only one affected patient. In COL group, \n\nAE most frequently found were: erythema (12%), crusts (5%), peeling  (4%) and edema (4%). \n\nThere was no difference in AE frequency between the groups (p=0.34) (table 3).  \n\nAt T15, 60% patients preferred MAL-PDT, 28% preferred COL and 12% have no \n\npreference between two treatments (p=0.06). \n\n \n\n \n\nTable 3: Adverse events 15 days after treatment \n\nAdverse Events - n(%) COL group MAL-PDT group \n\nAbsent 9 (25) 12 (33) \n\nMild 26 (72) 24 (67) \n\nModerate 1 (3) 0 (-) \n\nSevere 0 (-) 0 (-) \n\n \n\nDiscussion \u2013 Conclusions \n\nThis study indicates that 0.5% colchicine cream and MAL-PDT are effective in the \n\ntreatment of SFC, without significant difference between them. \n\n Topical colchicine has already been studied in other cutaneous diseases, and also for the \n\ntreatment of AK in concentrations from 0.5% to 1%, with reduction of up to 77% in the AK \n\ncount15,16. The most recent trial with colchicine compared it with topical diclofenac 3%, b.i.d \n\nduring 6 weeks, and it has demonstrated efficacy of approximately 50% in reduction of the area of \n\nthe AKs, with good aesthetic results and without significant AE, in agreement with our results33. \n\n Conversely, MAL-PDT has been extensively studied in the last decade, with good results \n\nin SFC treatment, reduction of recurrences of premalignant lesions and non-melanoma skin \n\ncancer. Moreover, it requires fewer treatments and few side effects, as well as aesthetic \n\nsatisfactory results. Nevertheless, it is an expensive treatment for field cancerization and can \n\ncause variable local pain along each PDT session 34. \n\n One single session of MAL-PDT seems to be enough to treat thin AK, with responses up \n\nto 81%. However, two sessions of MAL-PDT are recommended for the hyperkeratotic lesions 35, \n\n\n\n \n37 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\nand with an interval of one week presents reduction of AK counting up to 89%, with low \n\nrecurrence of the lesions.  However, our patients have different grades of AK, but not only thin \n\nones, which decreases the comparability of our results with other studies.  \n\n Sunscreen can also reduce AK counting and stabilize SFC. In a double-blind controlled \n\nstudy with a SPF 17 sunscreen during six months, there was a reduction of 24% in AK counts, in \n\ncomparison to 18% in placebo, which means that regular sunscreen may help to reduce the AK \n\nincidence and consequently treat the SFC36. In our study, all subjects were oriented to use \n\nsunscreen SPF 30 regularly and had received sunscreen during the following. This procedure can \n\nimprove the final results of any AK treatment. \n\n AKs can evolve to reduction o r self-resolution in up to 21% of the cases within one year \n\nof follow-up37, which can influence the reduction of AK count in any trial. Nonetheless, it is \n\nadvisable to treat all AKs and the whole SFC because there is a risk of 5-20% to evolve to a \n\nsquamous celll carcinoma1,2. \n\n Both MAL-PDT and colchicine have mild or moderate AE in a predictable proportion of \n\npatients, easily resolved, in agreement with previously published results in the literature.  \n\nHowever, MAL-PDT was preferred, with marginal significance, probably due to reduced AE, pain \n\nonly during red light exposure and good aesthetic results within 15 days. Additionally, a single \n\nMAL-PDT session can be more affordable than 10 days of colchicine home use one. \n\n AKs are the main clinical manifestation of SFC, and most researchers consider its \n\ncounting as a proxy measurement of the field cancerization activity 38. Meanwhile, AK counting \n\nand clinical degree of AK were the most largely used outcome for treatment assessment in \n\nclinical trials.  Moreover, to date, there is no consensus about molecular markers of SFC activity. \n\n Epidermal atrophy and loss of nuclear polarization are hallmarks of photoaging and \n\nevidences chronic sun exposure. The reversion of these parameters by both treatments are \n\nevidence of their effects on keratinocyte proliferation and stabilization of their atypia.  Those \n\nfindings were also reported after MAL-TFD5. Upper dermis abnormalities (e.g. elastosis, \n\nmastocytes and vascularization) were not assessed in this study, as its purpose was to explore \n\nthe epidermal cancerization. \n\n Alterations in nuclear p53 expression are found in most human cancers39 and they are \n\nalso present in many cases of skin cancer, as well as these alterations can be found in SFC40,41. \n\nEpidermal p53 expression is increased by sun exposure and can lasts up to 360h after the \n\nexposure, in order to repair DNA damage and provide apoptosis to severe genomic damaged \n\n\n\n \n38 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\ncells42. Another previous study with PDT-MAL in SFC also assessed the expression of p53 and \n\ndisclosed just a slight decreased expression, without significant difference4,5, that reinforces our \n\nfindings regarding less effect of p53 due to PDT-MAL.  The repercussion of this finding in \n\ncarcinogenesis at 6-month follow-up is warranted.  \n\n Ki67 nuclear expression was studied previously in skin neoplasms and it is evidenced in \n\nAK, Bowen\u00b4s disease, SCC and  basal cell carcinoma. It indicates a rate of epithelium proliferation \n\nand a patterned expression in epidermis in each neoplasm was described41,43. To date, there is \n\nno study describing ki67 expression in the activity of SFC. In our results, only the quantification of \n\nKi67 was analyzed, but the pattern of SFC Ki67 expression is warranted. \n\n In general, both Ki67 and p53 are related to the degree of malignancy in cutaneous \n\nneoplasms. The quantitative and qualitative longitudinal evaluation of Ki67 and p53 epidermal \n\nexpression can suggest either proliferative and proapoptotic activity. Our results suggest that \n\nthese markers can help to assess the activity of SFC. \n\n This study has some limitations: it is monocentric, originated from a public service, \n\nwhich minimizes the generalization of the results. On the other hand, these characteristics \n\nimprove its internal validity because it provides homogeneity between groups. \n\n Forearms AK and SFC as well as the skin structure and photoexposition regimen are \n\ndifferent in the face, upper chest and scalp.  This can lead to a different natural history of \n\ncancerization as a different pattern of treatment response.  For this reason, the results of clinical \n\ntrials performed in other body topographies should not be directly compared to the results of \n\nforearms.  We also believe that trials enrolling patients with low-grade AK or a less active SCF \n\ncan show more favorable results to any treatment. \n\n Colchicine cream is a low cost drug, with good efficacy and safety profile s and can be \n\na suitable therapeutic strategy in cutaneous oncology. Other regimes, vehicles and \n\nconcentrations should be investigated to optimize drug performance, with better tolerability \n\nprofile. \n\n \n\nAcknowledgements:  \n\nWe would like to thank to Paulo Roberto Cardoso, official of TOXICAM (Department of \n\nPathology-UNESP-Botucatu), for its professionality and care with the histopatholog ical materials. \n\n\n\n \n39 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\n \n\nReferences \n\n1. Sch mitt JV,  Mio t HA. Actin ic kera tosis: a  clin ica l and ep ide miolog ica l revision . An Bras Der ma tol 2012;  \n\n87: 425-34. \n2. Salasche SJ.  Epid e mio logy o f a ctin ic kera tosis and squa mou s cell carcino ma . JAm Acad Der ma to l.  \n\n2000; 42: 4-7. \n3. Slaugh ter DP, Sou thwick H W, Smejkal W. Field canceriza tio n in oral stratifie d squa mo us ep itheliu m;  \n\nclinical implications of multicentric origin. Cancer 1953; 6: 963-8. \n4. Torezan LA, Fe sta-Neto  C. Cu tan eous fie ld canceriza tion : clin ica l, h istopa tholog ica l and  therapeu tic \n\naspects. An Bras Dermatol 2013; 88: 775-86. \n\n5. Szeimies RM, Torezan L, Niwa A, et al. Clinical, histopa tho logical and immu nohistoche mica l \nasse ssmen t o f h u man skin field cancer iza tion be fore and a fter pho todyna mic therapy. Br J Derma to l \n2012; 167: 150-9. \n\n6. Ulrich C. Topical treatment of field cancerization. Cancer Treat Res 2009; 146:439-46. \n7. Hagele TJ, Levender MM, Davis SA, e t a l. Practice trends in the trea tmen t o f actinic kera to sis in the  \n\nUnited Sta tes: 0.5%  fluorouracil and co mbina tion cryotherapy plus fluorouracil are underused desp ite  \nevidence of benefit. J Cutan Med Surg 2012;16:107-14 \n\n8. Lebwohl M,  Swan son N, Anderson  LL, e t al.  Ingeno l meb u ta te ge l for a ctinic kera to sis. N Engl J Med.  \n2012; 366 (11):1010\u20139. \n\n9. TL Tester man, JF Ger ster, LM Imbertson, e t al. Cy tokine indu ctio n by the immuno modu la tors \n\nimiquimod and S-27609. J Leukoc Biol 1995; 58:365\u201372. \n10. Ianhez , Fleury LF, Jr., Miot HA, e t al. Re tinoid s for prevention and trea tmen t o f a ctin ic kera to sis. An  \n\nBras Dermatol 2013;88:585-93. \n\n11. Wo lf JR, Taylor JR, Tschen E. Topical 3%  diclo fenac in 5%  hyaluronan  gel in the trea tme n t of actinic \nkeratoses. Int J Dermatol 2001; 40:709\u201313. \n\n12. Morton C A, McKenna KE, Rho des L E. Guide line s for top ica l pho to dynamic therapy: upda te. Br J \nDermatol 2008;159:1245-66. \n\n13. Konda C, Rao AG. Colchicine in dermatology. Indian J Dermatol Venereol Leprol 2010;76:201 -5. \n14. Falkson G. Some aspects of the use of cytostatic drugs in dermatology. S Afr Med J 1966;40:339-42. \n15. Grima ?tre M,  Etienne A, Fa th i M.  Topical co lch icin e therapy for a ctin ic kera to ses.  Der ma tology  \n\n2000;200:346\u20138. \n16. Akar A,  B\u00fc len t Ta ?tan H,  Erbil H  e t a l. Efficacy an d sa fe ty assessmen t o f 0. 5%  and 1%  colch icine  \n\ncream in the treatment of actinic keratoses. J Dermatolog Treat. 2001;12(4):199 \u2013203. \n\n17. Wiegell SR. Upda te on ph o todynamic trea tmen t for actin ic keratosis. Curr Probl Derma to l \n2015;46:122-8. \n\n18. Torezan L, Niwa AB, Ne to CF. Photo dynamic therapy in der ma tology: basic prin cip les. An Bras \nDermatol 2009;84:445-59. \n\n19. Braathen  LR, Mor ton CA, Basse t-Seguin  N, e t al.  Pho todyna mic therapy for skin field can ceriza tion:  \nan in terna tiona l con sensu s. In terna tional So cie ty for Pho todyna mic Therapy in Derma to logy. J Eur  \nAcad Dermatol Venereol 2012;26:1063-6. \n\n20. Guimarae s CO, Baga tin E, Guadanh im LR, e t a l. Develop men t and Valida tion o f a Clin ica l Scale for  \nthe Evaluation of Forearm Skin Photoaging. J Cutan Med Surg 2015; 19: 380-7. \n\n21. Anwar J, Wrone DA, Kimya i-Assa di A, e t a l. The develop men t o f a ctin ic keratosis in to invasive  \n\nsqua mous cell carcino ma: Eviden ce and evolving classifica tion sche mes. C lin in Der ma to l 2004;  \n22(3):189\u201396. \n\n22. Brianezi G, Min icu cci EM, Marque s ME, e t al. Evalua tion ep ider mal p53 immuno stain ing by digita l \nimage analysis. Skin Res Technol 2013;19: e108-12. \n\n23. Issa  MCA, Manela-Azulay M.  Pho todynamic therapy: litera ture review and  iconogra fic do cu men ta tion.  \nAn Bras Dermatol. 2010;85(4):501-11. \n\n24. Olse n EA, Aberne thy ML, Kulp-Shorte n C et a l. A double-b lind, vehicle-con tro lled study evaluating  \n\nma soproco l crea m in the  trea tmen t o f actinickera to ses o n the he ad and neck. J Am Acad  Derma to l \n1991; 24: 738\u201343. \n\n25. Cockerell CJ. Histopa thology o f incipien t in traepider mal squa mou s cell ca rcino ma (\u201cactinic \n\nkeratosis\u201d). J Am Acad Dermatol. 2000;42(1 pt 2):11\u20137. \n\nhttp://www.sciencedirect.com/science/journal/0738081X/22/3\nhttp://www.sciencedirect.com/science/journal/0738081X/22/3\n\n\n \n40 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                       Manuscrito \n\n \n\n26. Ishiba shi H, Suzu ki T, Su zuki S, e t a l. Sex steroid hor mone recep tors in hu man thymo ma . J Clin  \n\nEndocrinol Metab 2003; 88(5): 2309-17. \n27. Baga tin E, Mio t HA. How to de sign a nd write a  clinical research proto col in Co sme tic Der ma to logy. An  \n\nBras Dermatol 2013; 88: 69-75. \n28. Norman GR, Streiner DL. Biostatistics: the bar e essentials: Bc Decker Hamilton; 2008. \n\n29. Siddiqu i O, Ali M W. A co mparison o f the rando m-e ffects pa ttern mix ture mod el with last-observa tion-\ncarried-forward (LOCF) analysis in long itudin al clin ica l trials with dropou ts. Journ o f Biophar m Sta t \n1998; 8(4): 545-63.  \n\n30. Mio t, HA. Assessin g norma lity o f da ta in clinical and experimen ta l trials. J Va sc Bra s. 2017(ahead o f \nprint) \n\n31. SPSS. IBM SPSS statistics for Windows, version 24. New York: IBM Corp 2016.  \n\n32. Overall JE, Doyle SR. Estima ting sa mp le sizes for repea ted mea suremen t designs. Con trol Clin  \nTrials. 1994;15(2):100-23. \n\n33. Faghihi G, Elah ipoor A,  Iraji F, e t a l. Top ica l colchicine gel versu s d iclo fenac sod iu m gel for the  \ntreatment of actinic keratoses?: A Randomized, Double-Blind Study. Adv in Med;2016:6\u201311. \n\n34. Togsverd-Bo K, Lerche  C, Poulsen T,  e t a l. Pho todyna mic therapy w ith top ica l me thyl- and  \nhexylamino levulina te for prophylaxis and trea tmen t o f UV-indu ced SCC in hairle ss mice. Exp Derma to l \n2010; 19: e166\u201372.  \n\n35. Tarsted t M,  Rosdah l I, Berne B, e t al. A rando mized mu lticen ter study to  co mp are two trea tmen t \nregime ns o f topical me thyl a minolevulina te (Me tvix )-PDT in actinic kera tosis o f the face an d sca lp.  \nActa Derm Venereol 2005; 85: 424\u20138. \n\n36. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J \nMed 1993; 329:1147-51. \n\n37. Harvey I, Frankel S, Marks R e t al. Non- mela no ma skin cancer and solar keratose s. I. Me thod s and  \ndescriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74:1302\u20137. \n\n38. Ianhez M,  Junior LFFF, Baga tin E, e t al.  The reliability o f co un ting  actinic kera tosis.  Arch  Derma to l \nRes 2013;841\u20134.  \n\n39. Hollste in M, Sidransky D, Vogelstein B, e t al. p5 3 Mu ta tion s in  Hu man Cancer s. Science , 1991;  \n\n253:49-53. \n40. Batinac T, Za molo  G,  Jon ji? N,  e t a l. p53  pro tein  expression  and cell pro lifera tion  in  non -neopla stic \n\nand neoplastic proliferative skin diseases. Tumori, 2004, 90(1): 120\u20137. \n\n41. Marinescu A, Stepa n AE, Margarite scu C, e t al. P5 3, p16 and Ki67 immunoexpression in cu taneou s \nsquamous cell carcinoma and its precursor lesions. Rom J Morphol Embryol 2016, 57(2):691 \u20136. \n\n42. Hall P A, McKee PH,  Menage HD, e t al. H igh levels o f p53 pro tein in U V-irradia ted nor ma l hu man skin.  \nOncogene.1993;8(1):203-7. \n\n43. Taghini S,  Halimi M , Baybordi H. Expression  o f P27, Ki67 and  P53 in squa mous ce ll carcino ma,  \nactinic keratosis and Bowen disease. Pak J Biol Sci 2009, 12(12):929-33. \n\n \n\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=12727990\nhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=12727990\nhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Overall%20JE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=8205802\nhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Doyle%20SR%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=8205802\nhttps://www.ncbi.nlm.nih.gov/pubmed/8205802\nhttps://www.ncbi.nlm.nih.gov/pubmed/8205802\nhttps://www.ncbi.nlm.nih.gov/pubmed/8093810\n\n\n \n41 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                      Conclus\u00f5es \n\n \n\n4. CONCLUS\u00d5ES \n\n \n\n \n\n Colchicina 0,5% creme duas vezes por dia por 10 dias e sess\u00e3o \u00fanica de MAL-TFD \n\nforam eficazes e seguras no tratamento do campo de canceriza\u00e7\u00e3o cut\u00e2neo.  \n\n Ambos os tratamentos promoveram redu\u00e7\u00e3o do escore de gravidade das QAS, da \n\nintensidade de QAs e do n\u00famero de QAs, sem diferen\u00e7a entre os grupos.  \n\n Ambos os tratamentos promoveram melhora do aspecto do campo de canceriza\u00e7\u00e3o \n\natrav\u00e9s da redu\u00e7\u00e3o da escala de fotoenvelhecimento dos antebra\u00e7os,  sem diferen\u00e7as entre si \n\n \u00c0 an\u00e1lise histopatol\u00f3gica, houve redu\u00e7\u00e3o do KIN escore e melhora da espessura epitelial \n\nem ambos os grupos, tamb\u00e9m sem diferen\u00e7as entre si.  \n\n \u00c0 an\u00e1lise imunohistoqu\u00edmica, houve redu\u00e7\u00e3o da express\u00e3o de Ki67 em ambos os \n\ngrupos, sem diferen\u00e7as entre si; a express\u00e3o de p53, entretanto, reduziu no grupo COL e \n\naumentou no grupo TFD, de forma estatis ticamente significante. \n\n Colchicina e a TFD apresentaram baixo perfil de efeitos adversos com adequada \n\ntolerabilidade. \n\n Mais pacientes preferiram o tratamento com TFD que COL. \n\n \n\n\n\n \n42 \n\nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                    Perspectivas \n\n \n\n5. PERSPECTIVAS \n\n \n\n O campo de canceriza\u00e7\u00e3o cut\u00e2neo vem sendo intensamente estudado com o objetivo de \n\ncontribuir para a preven\u00e7\u00e3o de novas neoplasias cut\u00e2neas, e consequentemente reduzir a morbi -\n\nmortalidade em popula\u00e7\u00f5es de risco, expostas a altas taxas de radia\u00e7\u00e3o UV, cronicamente, sem \n\nfotoprote\u00e7\u00e3o, principalmente entre os mais idosos, os quais s\u00e3o mais acometidos por tumores \n\ncut\u00e2neos n\u00e3o-melanoma. \n\n Apesar dos in\u00fameros estudos na \u00e1rea, ainda n\u00e3o h\u00e1 uma forma objetiva e uniforme de \n\navalia\u00e7\u00e3o da atividade do campo de canceriza\u00e7\u00e3o.  A contagem de QA \u00e9 a forma mais utlizada; \n\nentretanto, ainda n\u00e3o h\u00e1 uma padroniza\u00e7\u00e3o na contagem de QAs para definir um campo de \n\ncanceriza\u00e7\u00e3o em atividade, gerando controv\u00e9rsias entre os estudiosos na \u00e1rea.  \n\n Marcadores moleculares da atividade do campo de canceriza\u00e7\u00e3o tamb\u00e9m s\u00e3o \n\nconflituosos na literatura, e devem ser melhor explorados (p.ex. survivina, d\u00edmeros de pirimidina, \n\ntenascina-C).  Ademais, o desenvolvimento de uma escala de contagem de QAs (sob valida\u00e7\u00e3o) \n\nque possa refletir as altera\u00e7\u00f5es moleculares do epit\u00e9lio afetado deve facilitar a estra tifica\u00e7\u00e3o do \n\nrisco individual e a condu\u00e7\u00e3o de ensaios cl\u00ednicos comparativos  mais breves. \n\n Estrat\u00e9gias de desenvolvimento de novos par\u00e2metros, sejam cl\u00ednicos ou laboratoriais, \n\npara a detec\u00e7\u00e3o precisa de um campo de canceriza\u00e7\u00e3o em atividade poder\u00e3o contribu ir para o \n\ndesenvolvimento de protocolos padronizados de tratamento e seguimento desses pacientes, \n\ncom consequente redu\u00e7\u00e3o de novas neoplasias cut\u00e2neas e de sua gravidade; de tal forma que \n\nas cirurgias sejam menos mutilantes e o risco de recorr\u00eancias e met\u00e1stases menor, com \n\nevidentes ganhos no sistema de sa\u00fade e, principalmente, na qualidade de vida dos pacientes \n\nexpostos ao risco. \n\n Finalmente, alternativas de baixo custo e boa ader\u00eancia para o tratamento do campo de \n\ncanceriza\u00e7\u00e3o, que superem os efeitos conhecidos dos filtros solares, devem ser incentivados a \n\nfim de difundir suas op\u00e7\u00f5es terap\u00eauticas, especialmente, entre pacientes menos favorec idos.  A \n\nexplora\u00e7\u00e3o de combina\u00e7\u00f5es de tratamentos de campo (p.ex. 5FU+calcipotriol, 5FU+COL), vias \n\nde aumento de disponibilidade epitelial (p.ex. drug delivery) ou regimes posol\u00f3gicos \n\nintermitentes, devem ser explorados a fim de maximizar os efeitos e aume ntar a ader\u00eancia. \n\n\n\n43 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                             Anexos \n\n \n\nANEXO 1: Termo de Consentimento Livre e Esclarecido \n\n(T ERMINOLOGIA OBRIGAT \u00d3RIA EM AT ENDIMENTO A RESOLU\u00c7\u00c3O 466/12 \u2013CNS-MS) \n\nVoc\u00ea foi atendido(a) no ambulat\u00f3rio geral de dermatologia da Unesp e convidado a participar do projeto \nde pesquisa chamado EFIC\u00c1CIA E SEGURAN\u00c7A DO CREME DE COLCHICINA 0,5% VERSUS \nTERAPIA FOTODIN\u00c2MICA COM AMINOLEVULINATO DE METILA NO TRATAMENTO DO CAMPO \nDE CANCERIZA\u00c7\u00c3O CUT\u00c2NEO: UM ENSAIO CL\u00cdNICO RANDOMIZADO , que pretende comparar o \nefeito de duas formas de tratamento para as les\u00f5es pr\u00e9-malignas dos seus antebra\u00e7os (chamadas \n\nqueratoses act\u00ednicas):  colchicina em creme e a terapia fotodin\u00e2mica. \n\nA pesquisa consta em avaliar seus antebra\u00e7os, realizar uma bi\u00f3psia (remo\u00e7\u00e3o de um pequeno fragmento \nde pele) e, submeter cada antebra\u00e7o a um dos tratamentos, para compara\u00e7\u00e3o. Ambos os tratamentos s\u00e3o \nefetivos, ou seja, voc\u00ea estar\u00e1 em tratamento de qualquer forma. \n\nPara a terapia fotodin\u00e2mica, um dos antebra\u00e7os receber\u00e1 um creme e ser\u00e1 envolvido por um filme por 3h, \ndepois, receber\u00e1 um banho de uma luz especial por 8 minutos, para destruir as les\u00f5es. Esse \n\nprocedimento causa dor durante a aplica\u00e7\u00e3o da luz. \n\nPara o tratamento com colchicina, um outro creme ser\u00e1 fornecido para aplica\u00e7\u00e3o noturna em um dos \n\nantebra\u00e7os, por dez dias consecutivos.  \n\nNos dias seguintes, as \u00e1reas tratadas de vem evoluir com vermelhid\u00e3o, incha\u00e7o e pequenos ferimentos \nnas \u00e1reas doentes. Durante 60 dias ap\u00f3s o in\u00edcio do tratamento, voc\u00ea deve usar um filtro solar fornecido \n\npelos pesquisadores. \n\nAp\u00f3s 60 dias do tratamento, voc\u00ea ser\u00e1 reavaliado, de forma semelhante \u00e0 avalia\u00e7\u00e3o anterior, e um no vo \nfragmento de pele dos seus antebra\u00e7os ser\u00e3o removidos, para compara\u00e7\u00e3o. As bi\u00f3psias s\u00e3o realizadas \ncom anestesia local, o que pode gerar um leve desconforto no local, durante o procedimento. \n\nCaso voc\u00ea n\u00e3o queira participar da pesquisa, \u00e9 seu direito e i sso n\u00e3o vai interferir com o seu tratamento \n\nou a prefer\u00eancia de agendamento m\u00e9dico. \n\nCaso voc\u00ea precise de orienta\u00e7\u00e3o, ou aux\u00edlio m\u00e9dico decorrente do atendimento nesse ambulat\u00f3rio, deve \nprocurar o respons\u00e1vel pela pesquisa, Dr. H\u00e9lio Miot, no ambulat\u00f3rio de dermatologia da Unesp Botucatu, \n\nfone (14) 3811-6167. \n\nVoc\u00ea poder\u00e1 entrar em contato com o CEP atrav\u00e9s dos telefones: 3880 -1608 ou 3880-1609 para \n\nquaisquer informa\u00e7\u00f5es adicionais sobre este estudo. \n\nUma via desse termo de consentimento deve ser guardada com o sujeito da pesquisa, e outra ser\u00e1 \n\narquivada junto ao pesquisador. \n\n \n\nCONCORDO EM PARTICIPAR DA PESQUISA \n\nNome:................................................. Assinatura:............................................... \n\nProf. H\u00e9lio Amante Miot  Data:....../........../......Assinatura:................................... \n\nPesquisador: H\u00e9lio Amante Miot, Rua Manoel Fernandes Cardoso, 690, casa 14. Fone: (14)3882 -4922. \n\nE-mail: heliomiot@uol.com.br. CEP \n\n  \n\n\n\n44 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                             Anexos \n\n \n\nANEXO 2: Randomiza\u00e7\u00e3o dos antebra\u00e7os dos pacientes \n\nOrdem  do paciente Randomiza\u00e7\u00e3o Antebra\u00e7o direito Antebra\u00e7o Esquerdo \n\n1 0.13 COLCHICINA TFD \n\n2 0.49 COLCHICINA TFD \n\n3 0.79 TFD COLCHICINA \n\n4 0.19 COLCHICINA TFD \n\n5 0.95 TFD COLCHICINA \n\n6 0.88 TFD COLCHICINA \n\n7 0.64 TFD COLCHICINA \n\n8 0.07 COLCHICINA TFD \n\n9 0.18 COLCHICINA TFD \n\n10 0.77 TFD COLCHICINA \n\n11 0.37 COLCHICINA TFD \n\n12 0.27 COLCHICINA TFD \n\n13 0.89 TFD COLCHICINA \n\n14 0.56 TFD COLCHICINA \n\n15 0.92 TFD COLCHICINA \n\n16 0.45 COLCHICINA TFD \n\n17 0.10 COLCHICINA TFD \n\n18 0.95 TFD COLCHICINA \n\n19 0.82 TFD COLCHICINA \n\n20 0.87 TFD COLCHICINA \n\n21 0.47 COLCHICINA TFD \n\n22 0.20 COLCHICINA TFD \n\n23 0.45 COLCHICINA TFD \n\n24 0.23 COLCHICINA TFD \n\n25 0.01 COLCHICINA TFD \n\n26 0.81 TFD COLCHICINA \n\n27 0.49 COLCHICINA TFD \n\n28 0.32 COLCHICINA TFD \n\n29 0.48 COLCHICINA TFD \n\n30 0.44 COLCHICINA TFD \n\n31 0.11 COLCHICINA TFD \n\n32 0.36 COLCHICINA TFD \n\n33 0.94 TFD COLCHICINA \n\n34 0.89 TFD COLCHICINA \n\n35 0.90 TFD COLCHICINA \n\n36 0.80 TFD COLCHICINA \n\n\n\n45 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                             Anexos \n\n \n\nANEXO 3: Escala de fotoenvelhecimento dos antebra\u00e7os \n\n \n\nI tem \n\nGraus de Severidade \nFator \n\nMultiplicador \n\n0 1 2 3 4  \n\nQueratose \n\nact\u00ednica \n\n(superficial) \n\nNenhuma 1-2 3-5 6-10 >10 x 4 \n\nQueratose \n\nact\u00ednica \n\n(hipertr\u00f3fica) \n\nNenhuma 1 2 3 > 3 x 1 \n\nRugas Nenhuma \nRaras e \n\nfinas \n\nM\u00faltiplas e \n\nfinas \n\nM\u00faltiplas, finas e \n\nprofundas, por\u00e9m \n\nlocalizadas \n\nM\u00faltiplas, \n\nprofundas e \n\ndifusas \n\nx 9 \n\nLentiginoses 0-4 5-10 11-20 21-25 >25 x 4 \n\nP\u00farpura vis\u00edvel Nenhuma Sim x X x x 2 \n\nCicatrizes \n\nAtr\u00f3ficas \n\nEstreladas  \n\nNenhuma Sim x X x x 4 \n\nElastose Ausente Localizada Difusa x x x 8 \n\nPerda  de \n\nelasticidade \nAusente Localizada Difusa x x x 16 \n\n \n \n\n  \n\n\n\n46 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                             Anexos \n\n \n\nANEXO 4: Escala de Gravidade de Queratoses Act\u00ednicas \n\n \n\n  \n\nLes\u00e3o Eritema \n(0, 1 e 2) \n\nHiperqueratose \n(0, 1 e 2) \n\nInfiltra\u00e7\u00e3o \n(0 e 1) \n\nDi\u00e2metro \n(cm) \n\nEscore final \n(E+H+I)*Dm \n\n1      \n\n2      \n\n3      \n\n4      \n\n5      \n\n6      \n\n7      \n\n8      \n\n9      \n\n10      \n\n11      \n\n12      \n\n13      \n\n14      \n\n15      \n\n16      \n\n17      \n\n18      \n\n19      \n\n20      \n\n21      \n\n22      \n\n23      \n\n24      \n\n25      \n\n26      \n\n27      \n\n28      \n\n29      \n\n30      \n\n31      \n\n32      \n\n33      \n\n34      \n\n35      \n\n36      \n\nTOTAL      \n\n\n\n47 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                             Anexos \n\n \n\nANEXO 5: Parecer do Comit\u00ea de \u00c9tica em Pesquisa \n\n \n\n \n \n\n \n\n\n\n48 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                             Anexos \n\n \n\n \n\n \n \n\n \n\n\n\n49 \nColchicina versus T FD no campo de canceriza\u00e7\u00e3o                                                                             Anexos"}]}}}